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Abstract 
Engineering T cells with diverse mechanisms  
for improved tumor recognition precision 
by  
Jasper Zee Williams 
 
Engineered T cells are proven cancer therapeutics capable of executing potent 
antigen-dependent cell killing, and have gained FDA-approval after unprecedented 
results against certain blood cancers. However, successful treatment of solid tumors 
has been limited in large part by the lack of targetable antigens that are not also 
expressed in healthy tissues, as exhibited by ON-target OFF-tumor cross-reactive fatal 
toxicities seen in various human trials. An advantage of cell-based therapies is that cells 
can “compute” and execute more sophisticated programs than traditional drugs. 
Combinatorial antigen recognition has recently been introduced to overcome ON-target 
OFF-tumor toxicity limitations associated with traditional single antigen-targeted T cell 
therapies. This dissertation focuses on developing T cell engineering and biomaterials 
toolkits to expand the capabilities of combinatorial antigen-sensing T cell therapies. First 
presented is a set of approaches that use synNotch receptors and other synthetic 
receptors to program T cells with a diverse array of novel combinatorial antigen sensing 
circuits. It is shown that these Boolean logic-gated synNotch T cells can be engineered 
to sense both extracellular and intracellular antigens, target up to 3 antigens, integrate 
positive and negative regulation, and incorporate bispecific receptors. These abilities 
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could enable engineering therapeutic T cells with the ability to target truly tumor-specific 
antigen combination signatures identified via bioinformatic analysis of antigen 
expression in cancer versus healthy cells.  Also presented is a system to engineer T 
cells to recognize an orthogonal cue on biocompatible particles and incorporate this 
detection into combinatorial antigen-sensing circuits to specifically kill antigen positive 
tumor cells only in the presence of the particles.  Using particles to control therapeutic 
cell activity in the body has the potential to enhance safety by enabling dynamic, local 
user-control of engineered cells during treatment. Together, the technologies presented 
here facilitate the development of engineered T cells to safely target a broader range of 
cancers. The toolkits developed here can be used to engineer T cell therapies to target 
cancer cells with significantly improved precision by taking advantage of our modern 
capabilities in cancer informatics, cell engineering, and biomaterials.  
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Chapter 1 – Introduction  
 
ABSTRACT  
T cells engineered to recognize and kill tumor cells have emerged as powerful 
agents for combating cancer. Nonetheless, our ability to engineer T cells remains 
relatively primitive. Aside from CAR T cells for treating B cell malignancies, most T cell 
therapies are risky, toxic, and often ineffective, especially those that target solid 
cancers. To fulfil the promise of cell-based therapies, we must transform cell 
engineering into a systematic and predictable science by applying the principles and 
tools of synthetic biology. Synthetic biology uses a hierarchical approach – assembling 
sets of modular molecular parts that can be combined into larger circuits and systems 
that perform defined target tasks. We outline the toolkit of synthetic modules that are 
needed to overcome the challenges of solid cancers, progress in building these 
components, and how these modules could be used to reliably engineer more effective 
and precise T cell therapies. 
 
INTRODUCTION 
 
Challenges in engineering T cells to treat cancer  
T cells modified to express chimeric antigen receptors (CARs), which redirect 
cytotoxicity toward tumor cells (Fig 1.1A), have proven to be remarkably effective for 
treating B cell malignancies. Such treatments demonstrate high rates of response (70-
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90%) in clinical trials and have resulted in the first two FDA approved genetically 
modified cell therapies (Bouchkouj et al. 2018; O’Leary et al. 2018; Park et al. 2016). 
Nonetheless, there has yet to be a clear success engineering T cells to treat solid 
tumors (Klebanoff et al. 2016; Newick et al. 2016), which comprise ~90% of all cancer 
cases (Brown 2000). For this emerging platform to fulfil its potential, key challenges 
must be overcome to enhance the reliability, efficacy, and safety of T cell therapies.  
 CAR T cells targeting solid tumors have failed to mount effective and precise 
responses, due to several major challenges. First, there appears to be a lack of truly 
cancer-specific antigens expressed by solid tumor cells - most of which are derived from 
and share antigen expression with healthy epithelial cells. Thus, targeting solid tumor-
associated antigens has often resulted in severe and sometimes fatal on-target, off-
tumor killing of normal tissues that may express the antigen, albeit at lower levels 
(Johnson et al. 2009; Linette et al. 2013; Morgan et al. 2010, 2013; Parkhurst et al. 
2011). Second, T cells can be ineffective in immunosuppressive tumor 
microenvironments (TMEs) of many solid cancers (Binnewies et al. 2018). Third, there 
is a dearth of ways to control the T cells after they are transferred to the patient, 
presenting a strong safety concern that limits our ability to test and develop more potent 
T cells. Here we describe ongoing efforts to advance T cell engineering which hopefully, 
in the near future, will enable engineering of cells capable of executing the herculean 
combination of tasks necessary for effective treatment of solid cancers (Fischbach et al. 
2013; Geering & Fussenegger 2015; Lim & June 2017).  
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Immunotherapy meets synthetic biology: assembling a toolkit to systematically 
program therapeutic cells that can go the distance 
 
A major emerging theme in therapeutic T cell engineering is the application of 
synthetic biology principles (Chakravarti & Wong 2015; Chen & Chen 2019; Roybal & 
Lim 2017; Wu et al. 2015). The field of synthetic biology tries to understand cells as 
modular regulatory systems by investigating how cells are wired to give specific sense-
response behaviors and, more importantly, how to reprogram cells to perform novel 
functions (Cheng & Lu 2012; Kitada et al. 2018). Synthetic biology uses molecular parts 
to hierarchically assemble cellular devices and system that perform complex tasks. 
While synthetic biology began largely focused on engineering microbes (bacteria and 
yeast) (Cameron et al. 2014), in the last 5 years there has been an explosion of 
mammalian cell applications. Cells, especially T cells, are ideal chassis for therapeutic 
engineering, due to their ability to execute more intricate behaviors than traditional small 
molecule or biologic drugs. Using synthetic biology, scientists can in principle develop a 
toolkit of individual components that can be integrated in cellular circuits that hone the 
therapeutic potential of T cells. 
In this introduction, a variety of synthetic biology modules that could help enable 
the development of next generation engineered anti-cancer T cells will be discussed. 
The ability to engineer T cells combining various individual therapeutic modules into 
cohesive circuits will be necessary to eliminate solid cancers. We propose that synthetic 
biology efforts to engineer T cells should be driven by three major needs: (1) enhancing 
the tumor recognition precision to prevent healthy tissue cross-reaction/toxicity, (2) 
	 4	
boosting the ability to overcome suppressive TMEs, and (3) enabling user-control over 
engineered cells to enhance safety in patients (Fig 1.1B). The broader application of 
engineered T cells in patient care also faces other issues - such as cell source 
(allogeneic vs autologous (Qasim et al. 2017; Yang et al. 2015)), manufacturing 
(Esensten et al. 2016; Vormittag et al. 2018), and cost (Sarkar et al. 2018). These 
issues are critical for the future of engineered T cell therapies, but are beyond the scope 
of this discussion. The work in this thesis is most heavily focused on enhancing the 
precision of tumor recognition via combinatorial antigen recognition; however, the 
materials-based methods developed also open opportunities to improve our 
spatiotemporal control over T cell therapies while also improving their ability to 
overcome suppressive TMEs. 
 
SMARTER RECOGNITION OF CANCER 
 
Challenges of solid tumor recognition: balancing precision with flexibility  
 FDA-approved CAR T cells recognize a single B cell lineage antigen (CD19) and 
potently kill both malignant and normal B cells. While anti-CD19 CAR T cells are not 
truly cancer-specific, their ON-target, OFF-tumor effects cause manageable toxicities, 
as B cells are relatively expendable (Brudno & Kochenderfer 2016; Kochenderfer et al. 
2012). However, elimination of normal tissues sharing the CAR antigen usually cannot 
be tolerated. In fact, there have been several instances of lethal cross-reaction, where 
CAR T cells targeting tumor antigens have cross-reacted with normal tissues 
expressing low antigen levels, demonstrating the need for T cells that detect cancer 
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more precisely (Klebanoff et al. 2016; Rosenberg & Restifo 2015). Another tumor 
recognition challenge is that most cancers have heterogeneous antigen expression 
(Gerlinger et al. 2012; McGranahan & Swanton 2015, 2017; Sigalotti et al. 2004). While 
certain antigens may be expressed by many cancer cells within a tumor, often there are 
tumor cells with no or low levels of antigen, which can lead to the development of tumor 
resistance. Thus, CAR T cells targeting a single antigen lack the flexibility to capture 
heterogeneous antigen expression patterns in solid tumors (Chen et al. 2018). To 
improve targeting specificity and flexibility, synthetic biology approaches are being used 
to program T cells to recognize combinations of antigens, sense antigen density, and 
target heterogeneous antigens (Ebert et al. 2018) (Fig 1.2A). 
 
Combinatorial antigen recognition can improve tumor targeting precision 
One approach to improve tumor targeting precision is to engineer T cells with 
Boolean AND-gate recognition – T cells that only kill in response to sensing two 
antigens on cancer cells and spare healthy cells expressing either individual antigen. An 
early AND-gate strategy draws inspiration from the two-signal model for T cell activation 
(Chen & Flies 2013). The primary signal occurs when the TCR binds its cognate 
antigen; however, the primary signal by itself is insufficient to enable full T cell activation 
and proliferative response. A secondary signal from a co-stimulatory receptor is 
required to achieve full activation. FDA-approved CAR T cells combine both primary 
(CD3ζ) and co-stimulatory (CD28 and/or 41BB) signaling within one receptor. To 
engineer AND-gate CAR T cells, the primary and co-stimulatory signals can be split 
between two receptors each targeting a different antigen (Kloss et al. 2013; Wilkie et al. 
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2012) (Fig 1.2B). In this strategy, T cells are co-transduced with: (1) a CAR with a low-
affinity single-chain variable fragment (scFv) targeting antigen A and the CD3ζ signaling 
domain and (2) a chimeric co-stimulatory receptor (CCR) with an scFv targeting antigen 
B and a costimulatory signaling domain. T cells engineered with a CAR and CCR could 
kill target cells that expressed just the CAR antigen in vitro but, after scFv affinity tuning, 
both antigens were required to achieve optimal clearance of mouse xenograft tumors. 
Recently, our lab developed a new class of receptors called synthetic Notch 
(synNotch) receptors that can be used to build even more robust AND-gates (Morsut et 
al. 2016; Roybal et al. 2016a,b). SynNotch receptors (based on the native Notch 
receptor) use an extracellular recognition domain (e.x. scFv) to detect a target antigen. 
Binding of the target triggers a proteolytic cleavage event that releases the intracellular 
domain of the receptor. In the synNotch receptor, this domain is a synthetic transcription 
factor, that when released, can enter the nucleus and drive expression of user-specified 
transgenes linked to the responsive promoter. Thus, synNotch circuits require 
transfection of the receptor and the response promoter. We have shown that T cells 
engineered with synNotch-driven CAR expression can function as highly precise and 
robust AND-gates, sparing single-antigen but killing dual-antigen tumors in preclinical 
mouse models (Fig 1.2C). The synNotch-CAR AND-gate strategy has shown 
significantly greater in vitro killing specificity for dual-antigen cancer cells than the CAR-
CCR strategy – the fact that the mechanism of AND-gating requires that the T cells 
transit through a series of sequential cell states (unprimed, primed, activated) makes 
activation by single antigen cells very limited. The ability to precisely discriminate single 
antigen cells could be very important when the CAR antigen is also expressed by a 
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highly sensitive organ, such as the brain or lung. More recently, because of their 
flexibility and modularity we have shown that synNotch receptors can be harnessed in 
combination with CARs and TCRs to generate a wide variety of different Boolean gates 
for diverse combinatorial antigen sensing applications (see Chapter 2). 
NOT-gates are important, yet underdeveloped antigen recognition modules that 
inhibit T cells from killing cross-reactive normal cells. T cells engineered with A AND-
NOT B circuits are activated by antigen A but dominantly inhibited by antigen B. 
Employing NOT-gates in combinatorial antigen recognition circuits should help prevent 
toxicities to healthy tissues known to also express the CAR antigen. The only published 
NOT-gate method for engineered T cells relies on expression of an inhibitory CAR 
(iCAR) that fuses an extracellular antigen-specific scFv to an intracellular inhibitory 
signaling domain (e.x. programmed cell death protein PD1 or CTLA4) (Fedorov et al. 
2013) (Fig 1.2D). Co-expression of an iCAR with a CAR can prevent T cell killing of 
target cells that express the iCAR antigen. iCAR inhibitory effects are temporary and 
reversible, which is desirable for T cell NOT-gates. However, iCARs’ ability to inhibit T 
cell killing is highly dependent on high receptor and antigen expression levels and the 
CAR signaling architecture. Thus, we need to develop more robust and versatile T cell 
NOT-gates, as bioinformatic analysis of antigen expression patterns in a variety of 
cancers and healthy tissues suggests that negative regulation will be the most 
discriminatory component in combinatorial antigen-recognition circuits (personal 
communication, Olga Troyanskaya).  
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Sensing antigen density as a mechanism to discriminate between cancer and 
normal cells 
Despite the safety of antibody therapy targeting ERRB2, a CAR built using this 
antibody (Herceptin) caused fatal toxicity due to targeting normal cells expressing low 
levels of antigen (Morgan et al. 2010). It is now known that CAR T cells can target 
antigens expressed at significantly lower levels than traditional mAb therapies, 
increasing the risk of toxicity (Stone et al. 2012; Walker et al. 2017; Watanabe et al. 
2018). One approach to boost specificity of cancer recognition is to incorporate antigen 
density sensing, as tumors often overexpress antigens found at lower levels in normal 
tissues. Density sensing was first demonstrated by lowering CAR scFv affinity to only 
recognize antigen overexpressing cells (Caruso et al. 2015; Liu et al. 2015). An affinity-
tuned T cell should robustly kill tumor cells overexpressing the antigen and spare 
normal cells expressing physiologic levels (Fig 1.2E). To achieve affinity-tuned CAR 
recognition of a wide-pool of antigens, it is likely that specific screens will need to be 
carried out to generate lower affinity antibodies than are generated using conventional 
methods (Lim & June 2017b).   
Our lab is exploring alternative methods to engineer antigen density sensing in T 
cells. New circuits that incorporate antibody affinity, receptor expression level, and 
positive feedback can achieve even higher discrimination based on antigen density than 
by tuning CAR scFv affinity alone (unpublished data). Moving forward, combinatorial 
antigen recognition circuits could also be improved by integrating density sensing 
capabilities.  
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Overcoming antigen loss or heterogeneity by co-targeting multiple antigens for 
killing  
Another disadvantage of single-antigen targeted CARs is that cancer cells within 
tumors often heterogeneously express antigens or downregulate target antigen 
expression during treatment, both of which can cause escape. For example, cancers 
can lose expression of CD19 via a variety of genetic resistance mechanisms, and a 
disappointing proportion of patients who initially respond to CD19 CAR T cells relapse 
due to antigen loss (Bagashev et al. 2018; Orlando et al. 2018; Sotillo et al. 2015). 
These relapses sparked development of a variety of systems to program T cells with 
OR-gates that kill based on recognition of either CD19 OR CD22 (or another B cell 
antigen) (Zah et al. 2016; Zhao et al. 2019). Perhaps the most promising strategy is to 
engineer T cells with one CAR that has tandem antigen recognition domains separately 
targeting CD19 and CD22 (Fry et al. 2017; hultz et al. 2018; Qin et al. 2018). OR-gate 
CARs can also be built using a single binding domain that can bind multiple tumor 
antigens, which is usually achieved using a natural ligand as the targeting domain 
(Baumeister et al. 2018; Gilham & Maher 2017; Klampatsa et al. 2017; Lee et al. 2017). 
Other approaches include expressing up to three separate CARs (or CAR and TCR) 
targeting different antigens in the same T cell or dosing multiple T cells each targeting a 
different antigen (Bielamowicz et al. 2017; Chen et al. 2017; Ruella et al. 2016; Slaney 
et al. 2017). However, expressing one CAR with tandem recognition domains has 
shown the best efficacy in preclinical mouse models (Hegde et al. 2016).  
Engineering T cells to overcome antigen heterogeneity is critical when targeting 
solid tumors. For example, in glioblastoma multiforme a subset of patients express a 
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truly tumor-specific antigen, deletion variant III of the epidermal growth factor receptor 
(EGFRvIII); however, EGFRvIII is heterogeneously expressed, and a CAR T cell clinical 
trial targeting EGFRvIII failed to observe any tumor regression despite evidence of 
killing EGFRvIII-positive cancer cells (O’Rourke et al. 2017). Thus, generating CAR T 
cell systems that are specific enough to prevent toxicities but also flexible enough to 
detect heterogeneous antigen expression patterns will be critical for treating solid 
tumors. We are currently exploring how synNotchà CAR circuits could be used to prime 
based on recognition of a heterogeneous antigen like EGFRvIII, but then kill based on a 
more homogeneous, though less specific antigen (unpublished). Overall, approaches 
that allow T cells to integrate information across multiple cells in a tumor would be 
powerful tools in overcoming heterogeneity, and could be another unique advantage of 
cell therapies. 
 
 
OVERCOMING THE SUPPRESSIVE TUMOR MICROENVIRONMENT 
 
Multiple suppressive mechanisms limit T cell activity within solid tumors 
Solving the recognition problem to safely target cancer cells is only one piece of 
the puzzle for CAR T cells. Solid tumors create microenvironments that limit immunity 
using immunosuppressive factors such as inhibitory cells (e.x. Tregs), soluble signals 
(e.x. TGF-b), cell-cell contact ligands (e.x. PD1 axis), and physical barriers (extracellular 
matrix [ECM]) (Fig 1.3). Tumor microenvironments (TMEs) are also characterized by 
hypoxia and nutrient deprivation that metabolically T cells (Anderson et al. 2017; 
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Binnewies et al. 2018; Jerby-Arnon et al. 2018). CAR T cell clinical trials for solid tumors 
have produced disappointing results; therefore, we need better ways to engineer T cells 
to traffic to, infiltrate into, and overcome suppressive signals in TMEs. Synthetic biology 
can help develop a versatile toolkit of modularly combinable parts to engineer disease-
specific T cells with customizable circuits to overcome the unique suppressive 
mechanisms presented by different tumors types.  
 
Improving T cell trafficking to and infiltration into tumors 
CAR T cell therapy for solid tumors is limited by trafficking and infiltration (Idorn & 
thor Straten 2018; Slaney et al. 2014). Since blood cancers circulate in the same 
compartments as CAR T cells, engineered tumor-homing hasn’t been necessary. 
However, solid cancers are outside of the lymphoid circulation; therefore, synthetically 
homing T cells to solid tumors could help. To make things more difficult, tumors often 
secrete chemokines that prevent T cell homing (Harlin et al. 2009), and T cells often 
have incompatible chemokine receptors for chemokines found in tumors (Griffith et al. 
2014). To enhance tumor homing, groups have co-transduced CAR T cells with 
chemokine receptors corresponding to chemokines found in particular tumors. This 
approach has been tested in preclinical mouse models of Hodgkin’s lymphoma, 
mesothelioma, and neuroblastoma (Craddock et al. 2010; Kershaw et al. 2002; Moon et 
al. 2011; Stasi et al. 2009).  
Rather than relying on endogenous chemokine/chemokine receptor pairs, our 
group has shown that fully synthetic systems can control cell motility. Using a G protein-
coupled receptor modified to respond to a bioinert drug, we engineered immune cells 
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with drug-directed migration (Park et al. 2014). This technology can be combined with a 
drug releasing bead implanted at a disease site to direct only engineered cells to 
migrate towards the drug. Still, we need better methods to control cell trafficking, and 
new strategies to enable recruitment of tunable quantities of engineered cells to tumors 
would significantly push the field forward.  
 Solid tumors also have physical barriers that pose additional challenges to T 
cells. ECM in solid tumors limits T cells’ penetration and aggregation (Peranzoni et al. 
2013; Salmon et al. 2012). Heparan sulfate proteoglycan (HSPG) is an important tumor 
ECM component. By expressing an HPSE-degrading enzyme in CAR T cells, a group 
achieved increased infiltration and antitumor activity in preclinical tumor models 
(Caruana et al. 2015) (Fig 1.3). However, without some form of local regulation, T cells 
with ECM-degrading payloads may cause toxicity. 
 
Overcoming immune checkpoint and cytokine inhibition 
Another class of mechanisms that cancers use to inhibit immunity is expression 
of immunosuppressive ligands or cytokines (Iwai et al. 2002; Leach et al. 1996; 
Mariathasan et al. 2018; Rabinovich et al. 2007). These signals can critically regulate T 
cell fate/function and decrease antitumor efficacy. One approach to address this hurdle 
is to reduce T cells’ inhibitory signaling capabilities. CAR T cells with PD-1 expression 
disrupted by Cas9-mediated gene editing (Rupp et al. 2017) or TALEN editing (Menger 
et al. 2016) have enhanced clearance of PD-L1-expressing tumors (Fig 1.3). 
Alternatively, CAR T cells engineered to constitutively secrete mAbs/scFvs blocking the 
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PD-1 axis led to local accumulation of the checkpoint inhibitors within mouse xenograft 
tumors and enhanced clearance (Rafiq et al. 2018; Suarez et al. 2016).  
Another approach to overcome suppressive signals is to express dominant-
negative receptors that act as ligand sinks and block signaling. Transforming growth 
factor β (TGF-β) is a cytokine secreted by tumors that can cause apoptotic effects (Li et 
al. 2006); however, tumors can avoid the apoptotic effects by expressing a 
nonfunctional TGF-β receptor (Knaus et al. 1996; Park et al. 1994). Overexpressing a 
signaling-incompetent TGF-B receptor in CAR T cells has enhanced proliferation, 
cytokine secretion, and persistence in preclinical models (Bollard et al. 2002; Kloss et 
al. 2018) (Fig 1.3). A potentially more potent but also more risky approach to overcome 
suppression is to synthetically rewire a naturally inhibitory input to a stimulatory output. 
For example, expression of a chimeric molecule that swaps the cytoplasmic tail of the 
CD200R inhibitory receptor with that of the co-stimulatory receptor CD28 causes 
enhanced T cell proliferation and effector function in preclinical models (Kretz-Rommel 
et al. 2007; Oda et al. 2017). Other similar receptors that block inhibitory signals or 
transduce them into stimulatory signals have also been developed to help CAR T cells 
overcome TMEs (Liu et al. 2016; Yamamoto et al. 2019) (Fig 1.3). While promising 
ways to boost efficacy, interfering with these inhibitory checkpoint and cytokine 
pathways in engineered T cells will require tight regulation to avoid activating 
autoimmunity (June et al. 2017).  
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Overcoming metabolic suppression – new checkpoints on the block  
Due to high nutrient consumption rates by cancers cells, tumors create 
suppressive metabolic microenvironments that inhibit immunity (Pearce et al. 2013; 
Wang & Green 2012). For example, glycolytic metabolite phosphoenolpyruvate (PEP) 
sustains nuclear factor of activated T-cells (NFAT) signaling and effector function, and 
insufficient PEP levels cause diminished anti-tumor T cell responses. Overexpressing 
PEP carboxykinase 1, which catalyzes PEP production, in T cells led to greater effector 
function (Ho et al. 2015). These results show that modulating T cell metabolism can 
enhance function.  
Given nutrient deficits in solid tumors, CAR T cells’ metabolic characteristics are 
critical for effective therapy. CAR co-stimulatory domain identity is known to influence T 
cell metabolic state. For example, CD28 CAR co-stimulation drives T cell differentiation 
into effector memory cells with enhanced glycolysis, while 4-1BB co-stimulation 
promotes central memory T cell formation with increased respiratory capacity, increased 
fatty acid oxidation, and enhanced mitochondrial biogenesis (Kawalekar et al. 2016). 
CAR T cell studies have shown that CD28 signaling leads to early proliferation but 
decreased persistence while 4-1BB signaling leads to increased persistence and lasting 
memory formation (Long et al. 2015; Zhang et al. 2007). There is a clear need for 
improved CAR co-stimulatory signaling to give CAR T cells the most metabolically 
advantageous system to balance proliferation and persistence. 
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Promoting T cell memory, proliferation, and persistence 
Methods to induce memory CAR T cells that balance proliferation and 
persistence would improve the efficacy of T cell therapies for both hematological and 
solid cancers. A new approach to solve this problem is by reducing the strength or 
duration of CAR signaling. One study showed that using CARs with a single 
immunoreceptor tyrosine-based activation motif (ITAM), rather than three ITAMs 
normally found in CD3ζ, led to highly functional T cells with enhanced persistence in 
preclinical tumor models (Feucht et al. 2019). The reduced activation signal from the 
CAR with a single ITAM caused especially profound increases in efficacy relative to 
traditional CARs in experiments infusing very low T cell numbers.  
Another approach is to regulate T cells’ epigenetic profile to maintain a 
proliferative state long-term. One study reported anti-CD19 CAR transgene insertion 
unexpectedly disrupting the epigenetic-regulator TET2 gene in one T cell during the 
lentiviral vector-mediated integration (Fraietta et al. 2018). The TET2 gene disruption 
caused this single T cell to proliferate massively in the patient, and at the peak of 
response 94% of CAR T cells were found to have expanded from that single clone. 
Demonstrating the ability to intentionally engineer this behavior, the group knocked 
down the TET2 gene and found that CAR T cell proliferation, persistence, and potency 
enhancing effects were recapitulated. Similar effects on CAR function have been 
achieved by expressing altered Myc proteins in engineered T cells to drive optimal 
proliferative phenotypes (personal communication, Crystal Mackall). While potentially 
promising, modifications that enhance T cell proliferation and persistence create the risk 
of causing T cells to become auto-reactive or cancerous. Thus, it may be important in 
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the future to not simply make constitutive changes to the T cells to increase their 
potency (i.e. constitutive expression or knock out of particular genes), but rather to 
make these changes inducible at the site of the tumor (Fig. 1.3). Smarter T cells that 
can autonomously sense when and where to amplify their potency and durability may 
be ideal. 
 
USER-CONTROL AND SAFETY 
 
Need to regulate modifications that enhance T cell activity to prevent dangerous, 
out-of-control immune activation 
Enhancing the potency of engineered T cells has been a major priority; however, 
if not carefully controlled, this could cause serious side effects. We currently lack robust 
ways to regulate engineered T cells once they are in patients. Enhanced safety 
measures, including methods for user control, will be critical to enable widespread 
adoption of CAR T cell therapy. Many methods are in development to control the 
strength, duration, and location of CAR T cell activity. Ultimately, the goal is to engineer 
T cells that can autonomously regulate themselves to prevent adverse events. 
However, even in the hypothetical context of self-regulating engineered T cells, 
interventional means to control cell activity during treatment are still desirable.  
 
Gene editing strategies to improve predictability and safety of engineered T cells 
The current standard approach engineers CAR T cells using viral vectors that 
permanently integrate transgenes in the genome (Esensten et al. 2016; Levine et al. 
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2017). Virally-transduced CAR T cells experience random integration, making them less 
predictable and reliable. This may result in unintended consequences- such as clonal 
expansion, oncogenic transformation, and variable expression of the transgene- that 
could be avoided if the transgene is integrated into a specific locus. One study directed 
the CAR transgene into the T-cell receptor α constant (TRAC) locus using 
CRISPR/Cas9 genome editing technology and found more uniform CAR expression 
with enhanced antitumor effects at lower doses of T cells, which could reduce side 
effects associated with infusing high T cell numbers (Eyquem et al. 2017).  
Gene editing has also been used to inactivate toxicity-related genes in CAR T 
cells. Cytokine release syndrome (CRS) is a major CAR T cell toxicity (Brentjens et al. 
2013; Brudno & Kochenderfer 2016). Although CRS can be managed with anti-IL-6R 
monoclonal antibody or glucocorticoid (Le et al. 2018; Maude et al. 2014a), it can still be 
life threatening (Porter et al. 2018). To prevent CRS, a group inactivated granulocyte 
macrophage colony-stimulating factor (GMCSF) gene, which has been known to 
promote CRS, in CAR T cells using TALENs (Sachdeva et al. 2019). Upon activation 
engineered CAR T cells with inactivated GMCSF induced decreased macrophage-
dependent secretion of CRS biomarkers, without impairing T cell cytotoxicity or 
proliferation. 
 
Drug-controlled synthetic systems to control T cell activity for increased safety  
 Many safety and control systems in development use small molecules or 
biologics to regulate the location, intensity, and/or duration engineered T cell activity. 
The earliest type of control system was kill switches to eliminate CAR T cells in case of 
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severe toxicity (Berger et al. 2006; Bonini et al. 1997) (Fig 1.4A). A popular kill switch 
for drug-induced CAR T cell apoptosis (iCasp9) was developed by fusing a modified 
human caspase 9 to the FK506 binding protein (FKBP) that dimerizes in the presence 
of a small molecule drug (Straathof et al. 2005). An advantage of this system is that the 
drug eliminates only engineered T cells and ignores native immune cells, and it has 
shown efficacy in both preclinical and clinical contexts (Diaconu et al. 2017; Stasi et al. 
2011). Furthermore, FDA-approved small molecules, such as rapamycin, can control 
iCasp9 switches with alternative heterodimerization domains and may face fewer 
regulatory hurdles (Stavrou et al. 2018).  
Systems have also been developed that use antibodies to eliminate engineered 
T cells. Compact epitope tag constructs with low probability of natural immunogenicity 
were built for binding by FDA-approved antibodies. FDA-approved antibodies Rituximab 
and Cetuximab have been used with CAR T cells expressing the corresponding 
truncated antigen epitope constructs for both ex vivo cell selection and in vivo cell 
depletion and tracking (Philip et al. 2014; Valton et al. 2018; Wang et al. 2011) (Fig 
1.4B). However, relying on antibody-dependent cellular toxicity to eliminate CAR T cells 
is risky in cancer patients with reduced immunity due to preconditioning or other 
previous chemotherapy.  
Rather than killing engineered T cells, another approach is to make CAR T cell 
activation dependent on a drug signal. Our group has developed ON-switch CARs that 
need to sense both an antigen and small molecule to activate T cells (Wu et al. 2015a) 
(Fig 1.4C). The ON-switch CAR separates the key intracellular signaling components 
from the extracellular antigen binding domain on separate polypeptides that contain 
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partner drug-inducible heterodimerization domains. The ON-switch CAR is inactive until 
it senses both heterodimerizing drug and antigen. This system allows T cell activity to 
be titratably and reversibly inhibited.  
Another group developed a system in which CD3ζ signaling is initiated by antigen 
binding while costimulatory signaling is independently controlled by a small molecule 
dimerizer (Foster et al. 2017). T cells with this system are designed to only full activate 
when both target-specific CD3ζ signal and small molecule inducible co-stimulatory 
signal are received; however, like the CCR AND-gate system, in vitro and some in vivo 
killing of CD3ζ CAR antigen positive cells occurs in the absence of dimerizer drug. Still, 
the same group showed that this drug-dependent co-stimulatory system could be used 
in the same CAR T cells as an orthogonal drug-dependent inducible Caspase-9-based 
safety switch (Duong et al. 2018). Robust, independent control of both CAR T cell 
expansion/persistence and death using orthogonal drug switches could enable strict 
modulation of therapeutic T cell population size throughout treatment. 
 
Adaptor-mediated CARs combine drug-controlled safety with ability to combat 
resistance by switching antigen targeting  
 FDA-approved CAR T cells lack activity control after antigen binding and do not 
allow for retargeting of different antigens without using a new CAR T cell product. To 
address these limitations, adaptor-mediated CARs split signaling and antigen-binding 
components between separates molecules (Cartellieri et al. 2016; Kudo et al. 2014; Ma 
et al. 2016). For example, in the peptide neo epitope (PNE) CAR system, T cells are 
engineered to express a CAR targeting a short, bio-orthogonal peptide tag. Under 
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normal conditions, the PNE CAR does not bind target tumors (Rodgers et al. 2016; 
Viaud et al. 2018) (Fig 1.4E). When a tumor-antigen specific antibody fragment fused to 
the PNE tag is introduced, anti-PNE CAR T cells are redirected to kill the tumors cells. 
This system allows for reversible titration of CAR activity without the need to eliminate 
the CAR T cell. Furthermore, the same engineered T cells can change targets by 
adding a different tag-fused antibody.  
Recently, a group developed a similar split, universal and programmable 
(SUPRA) CAR (Cho et al. 2018). The SUPRA CAR system is a two-component receptor 
system composed of various pairs of universal orthogonal receptors expressed by T 
cells and corresponding tumor-targeting scFv adaptors that engage the receptors 
through leucine zipper interactions. Antigen targeting can be swapped by changing 
adaptor, and signaling outcome is determined by the identity of the universal receptor. 
Like other adaptor-mediated CARs, the SUPRA CAR allows for reversible and titratable 
CAR activity, with added ability to send combinations of signals to T cells for functions 
such as combinatorial antigen sensing. 
 
Engineered biomaterials provide unique ways to control therapeutic T cells 
 For T cell therapies to achieve their potential and treat more cancer types such 
as solid tumors, it is crucial to improve methods to control T cells during both ex 
vivo culture/manufacturing and in vivo patient treatment.  Patients deaths in trials due to 
toxic reactions have made it painfully obvious that there is a particularly striking lack of 
options to control engineered T cells once they have been dosed and essentially set 
loose within a patient.  There has been a wide effort to find ways to modulate 
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engineered T cell therapies by using drugs that were originally developed to act on 
natural immune cell or other endogenous cell populations.  Although these efforts have 
helped to improve control over the efficacy and safety of T cell therapies, they have also 
demonstrated the risks for side effects due to using drugs that target both engineered 
and non-engineered cells.  More recently, our group and others have described 
methods to refine this effort by using biomaterials or small molecule/biologic drugs to 
specifically regulate engineered T cells.  To improve the ability to control engineered T 
cell therapies and improve patient outcomes, there is a need to develop modular, 
flexible platforms that can be deployed throughout manufacturing and treatment to send 
T cells user-controlled signals that can dynamically alter the treatment in a highly-
targeted manner. Ultimately, we believe that there is incredible promise for combining 
smart engineered T cells with smart biomaterials, biologics, and small-molecules to 
achieve more sophisticated spatiotemporal control over these powerful cell therapies.  
Chapter 3 will discuss the development of a biomaterial system to enhance user-control 
and enable in vivo spatiotemporal modulation of combinatorial antigen-sensing T cells. 
 
CONCLUSION AND OUTLOOK 
 
Adoptive T cell therapy for cancer is at an exciting but critical point in its 
development. The success and FDA approval of anti-CD19 CAR T cells for treatment of 
B-cell cancers has clearly demonstrated the powerful potential of using engineered 
immune cells to eliminate cancers. However, this technology is at a primitive stage, like 
aviation in the pioneering days of the Wright brothers. While it was clear that powered 
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flight was possible, it was a risky, life-threatening, and unreliable endeavor – a long way 
from the reliability and safety of modern commercial aviation. Similarly, today’s cell 
therapies are highly risky and unpredictable. Most attempts to engineer T cells to treat 
solid tumors have led to either ineffective outcomes or highly toxic cross-reactivity. 
  We want the power of synthetic biology to be harnessed to develop a new 
foundational platform for engineering more powerful, yet safer T cell therapies. We 
postulate that ideal cell therapies for attacking solid cancers must fulfil multiple functions 
– they must be designed to precisely recognize the cancer and not critical normal 
tissues, they must be able to overcome the suppressive TMEs, and we must be able to 
control their activity (Fig 1.5). Using synthetic biology, we should be able to generate 
more tools to program T cells capable of sensing and responding to various diseases in 
increasingly autonomous and regulated manners. Synthetic biology provides unique 
opportunities to overcome challenges identified with the first wave of T cell therapies. 
Synthetic biology principles and technology platforms should facilitate the broader 
scientific community’s ability to engineer improved, innovative T cell therapies. 
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Figure 1.1. CAR T cells and challenges facing them for solid tumors 
(A) Diagram of CAR T structure which includes extracellular recognition domain (single-
chain variable fragment) fused to intracellular TCR signaling domains (CD3z) and co-
stimulatory domains (e.g. CD28 or 4-1B binding to cancer antigen).  
 
(B) There are three major challenges for CAR T cells when treating solid tumors. CAR T 
cells must be able to precisely recognize solid tumors while preventing normal tissue 
cross-reaction, overcome suppressive tumor microenvironment, and be developed to 
have user-control/safety platforms. 
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Figure 1.2. Antigen sensing strategies to improve tumor targeting precision 
(A) The emerging synthetic biology toolkit for cell engineering allows for multi-antigen 
sensing T cells which enable smart sense-and-response approaches that can lead to 
more precise T cell activation and killing.  
 
(B) Chimeric costimulatory receptor (CCR) CAR T cells are transduced with a CAR that 
provides limited activation upon binding of one antigen. Only when both CAR and CCR 
antigens are bound, the T cells can have full activation enabling AND-gate logic.  
 
(C) SynNotch-CAR AND-gate allows for robust combinatorial antigen gating due to the 
sequential activation steps. The engineered T cells is initially unprimed and does not 
express the CAR until the synNotch receptor binds to antigen A. Once primed by 
antigen A, CAR is expressed and T cells can be activated and kill any cancer cells 
expressing antigen B.  
 
(D) Inhibitory CARs (iCARs) T cells cannot be activated when the iCAR engages a 
specific normal tissue antigen even if the CAR is engaging with its cognate antigen, 
allowing for NOT-gate logic.   
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(E) Conventional CAR (green) indiscriminately kills both normal cells expressing low 
levels of antigen and cancer cells expressing high level antigen. While density sensing 
circuit CAR (purple) can discriminate eliminate only the cancer cells expressing high 
levels of antigen. 
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Figure 1.3. Engineering T cells to overcome inhibitory tumor microenvironments 
T cells engineered with the conventional CAR T cells are susceptible to tumor immune 
suppression via checkpoints/activation-induced cell death ligands, inhibitory cytokines, 
and physical barriers (ECM). By equipping T cells with synthetic tools such as ECM 
degrading enzyme, deletion of PD-1 or Fas gene, expression of dominant-negative 
cytokine receptors, and enabling tumor-induced T cell responses. The next generation 
of CAR T cells are able to actively remodel the tumor microenvironment and become 
resistant to tumor suppression. 
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Figure 1.4. Methods to control T cell activity and population to enhance safety 
(A) A strategy for constructing a kill-switch CAR includes expressing an inducible 
caspase 9 with a drug-binding domain. When the small-molecule dimerizer is present, it 
initiates a signaling cascade leading to apoptosis of the engineered cell.  
 
(B) Truncated EGFR (tEGFR) can be expressed on T cells to be utilized as a kill-switch. 
Monoclonal antibody against the EGFR can be utilized to mediate antibody-dependent 
cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) and cause 
CAR T cells to lyse.  
 
(C) A strategy for constructing a ON-switch CAR includes splitting the key CAR 
components from the conventional CAR into two separate polypeptides that can be 
conditionally brought together when a heterodimerizing small-molecule agent is present.  
 
(D) Unlike the conventional CAR T-cell activation which is mediated by direct  
recognition of cancer antigen, adaptor mediated CAR engages with tumor cells by an 
adaptor, which include a peptide neo-epitope (PNE) specifically recognized by the anti-
PNE CAR and a scFv specific for cancer antigen. 
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Figure 1.5. Vision for next-generation therapeutic T cell engineering for solid tumors 
The next-generation of therapeutic T cells will need to be designed to precisely and 
effectively recognize cancer and not normal tissues, be able to overcome the 
suppressive microenvironment of the tumor, and users must be able to control their 
activity. Precise tumor biology analysis with synthetic immunology toolkit has the 
potential to provide T cells capable of overcoming solid tumors.  
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Chapter 2 – Programming a suite of multi-antigen pattern 
recognition circuits in therapeutic T cells 
 
ABSTRACT 
Tumor cells often differ only subtly from normal cells in their molecular features, 
thus it would be powerful if therapeutic immune cells could integrate as much 
information as possible to discriminate and kill tumor cells. Rather than using a single 
CAR or TCR to recognize a cancer based on a single antigen, it would be 
advantageous to integrate multiple receptors into combinatorial recognition circuits that 
take advantage of multifaceted differences present or absent in cancers. Here we 
develop a large toolkit of combinatorial Boolean circuits that link together synNotch 
receptors, CARs, TCRs and split CARs in different ways. This suite of circuits can 
program T cells to integrate information from 1-3 antigens, to detect combinations of 
both internal and extracellular antigens, and to integrate both positive and negative 
antigen selection. These pattern recognition circuits allow engineered T cells to 
precisely exploit the most unique and actionable features of a tumor.  
 
INTRODUCTION 
 
T cells engineered to recognize and kill cancers using chimeric antigen receptors 
(CARs) and T cell receptors (TCRs) have demonstrated remarkable clinical potential 
(June and Sadelain, 2018; Rosenberg and Restifo, 2015). But the broader clinical 
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application of therapeutic T cells to many cancer types is limited by the lack of 
targetable antigens whose expression cleanly distinguishes cancer cells from healthy 
cells (Klebanoff et al., 2016; Rosenberg and Restifo, 2015). This lack of antigen 
specificity is particularly true when targeting solid tumors - many of the potential CAR 
tumor antigen targets are also found in normal epithelial tissues, leading to observed 
toxic ON-target OFF-tumor cross-reaction (Johnson et al., 2009; Morgan et al., 2010, 
2013; Parkhurst et al., 2011). Cancer cells differ only slightly from normal cells in their 
molecular features, thus it is not surprising that targeting a single antigen is often 
insufficient to discriminate against normal tissues. 
Bioinformatic analysis, however, indicates that combinatorial antigen pattern 
recognition could enable far more specific cancer targeting (personal communication, 
Olga Troyanskaya). By taking advantage of unique combinatorial antigen signatures, 
rather than a single antigen, significantly higher discrimination could be achieved. 
Ideally, we would like to be able to engineer therapeutic T cells with flexible, tailored 
programs that are designed to recognize and exploit the most discriminatory features of 
the tumor. We would like to be able to build T cells that recognize combinations of both 
cell surface antigens and intracellular antigens (which represent ~75% of the proteome 
(Almén et al., 2009)). It would also be ideal to be able to integrate recognition of 2-3 
different antigens, and to be able to recognize them with diverse Boolean logical 
relationships:  AND gates for positive selection, NOT gates for negative selection, and 
OR gates for capturing heterogeneous antigen populations.   
Engineered living cell therapies, in principle, present a unique platform in which 
diverse molecular recognition circuits can be inserted, especially by harnessing modular 
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sensors such as synNotch receptors, which can drive expression of arbitrary genes in 
response to recognition of specific antigens (Morsut et al., 2016).  For example, we 
have previously shown that we can engineer therapeutic AND gate T cells that can 
precisely recognize a combination of two surface antigens: in this case we used a 
synthetic Notch (synNotch) receptor directed against antigen A to drive the expression 
of a CAR directed against antigen B. This sequential priming circuit leads to T cell 
activation and target cell killing only when the target cell expresses both antigen A and 
B on its surface (Roybal et al., 2016a). Success in engineering this basic AND gate, as 
well as other related advances, has led us to ask whether we can engineer a more 
complete set of sophisticated T cell circuits that could be flexibly deployed to identify 
those features that are most discriminatory in varied cancers. Can we diversify the 
recognition algorithms of therapeutic cells to fit the distinguishing features of different 
cancers?  
Here, we develop a suite of new T cell multi-antigen pattern recognition circuits 
that provide an array of ways to recognize cancers (Figure 2.1). With this set of circuits, 
we can now recognize nearly all possible classes of 2-3 antigen signatures. We show 
that we can combine synNotch and TCR sensors to build circuits that harness 
recognition of combinations of extracellular and intracellular antigens – thus tapping into 
the potential of the much broader pool of the intracellular proteome. We also show that 
we can use multiple synNotch and CAR sensors to build diverse circuits that 
simultaneously integrate recognition of up to 3 distinct antigens. More importantly, these 
circuits can be highly flexible in that specific antigens can be recognized in a positive 
way (AND gates, i.e. antigen is present in tumor) or in a negative way (NOT gate, i.e. 
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antigen is not present in tumor).  In particular, we have engineered a novel type of 
antigen-dependent NOT gate that harnesses apoptotic control to override T cell 
expansion. In addition, these recognition circuits can also incorporate OR gate 
functionality to capture a heterogeneous population of target cells. Thus, the mode in 
which each of the three individual antigens is utilized in recognition can be tailored 
independently. In principle, these new types of flexible cell recognition circuits, 
combined with bioinformatic analysis, can allow one to more effectively identify and 
exploit the most discriminatory features of a cancer within the complex antigen 
landscape that is presented by the human body.  
 
RESULTS 
 
Combining synNotch receptors and TCRs to integrate external and internal 
antigen recognition 
Given that intracellular antigens represent ~75% of the proteome and are further 
enriched amongst cancer antigens (Vogelstein et al., 2013), it would be ideal to 
incorporate intracellular antigen sensing capabilities into AND gate T cells. In prior 
studies, we demonstrated that synNotch receptors can be used to engineer AND gate T 
cells to recognize a combination of two surface antigens via synNotch-inducible 
expression of a CAR or bispecific T cell engager (Roybal et al., 2016a,b).  Thus, we 
reasoned that synNotch receptors could also be used to induce the expression of TCRs, 
which are able to recognize intracellular proteins in the form of peptides presented on 
major histocompatibility complexes (pMHC).   This kind of external-internal AND gate 
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could be useful to restrict the action of a promiscuous TCR to a specific subset of 
tissue/s, based on the expression of the priming (synNotch activating) antigen.  
Altogether, incorporating internal antigen recognition would increase the pool of 
possible antigen combinations to target. 
To engineer external-internal dual antigen AND gate T cells, we constructed and 
tested circuits in which synNotch receptors control the expression of TCRs. As a proof-
of-concept, we engineered human primary CD8+ T cells with an a-Her2 synNotch 
receptor (external antigen) controlling expression of an a-MAGE-A3 TCR (internal 
antigen; residue 112-120 peptide presented by HLA-A2) (Figure 2.2A). Clinical trials 
with forms of the a-MAGE-A3 TCR, used to target melanoma, have shown toxic cross-
reactivity with the brain.  Thus, the ability to gate its expression and activity with a 
second antigen would be very useful.  We used a multi-cistronic construct in which a 
synNotch-inducible promoter drove expression of both the TCR and a BFP reporter 
protein. We first verified that these constructs could be used to track TCR expression in 
a TCR-deficient Jurkat T cell line (Figure 2.8A).  
Since the engineered T cells should only express the a-MAGE-A3 TCR in 
response to a-Her2 synNotch priming, these T cells are predicted to only activate and 
kill target cells expressing both Her2 (synNotch priming antigen) and MAGE-A3 (TCR 
killing antigen) (Figure 2.2B). We co-cultured the engineered T cells with target T2 
lymphoblastoid cells presenting either Her2 only, MAGE-A3 only, or both Her2 and 
MAGE-A3.  As predicted, these T cells only show synNotch activation, and the 
subsequent expression of BFP and the a-MAGE-A3 TCR, in response to target cells 
presenting the synNotch antigen, Her2 (Figure 2.2C). More importantly, these 
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synNotch/TCR T cells showed robust AND gate behavior, killing target cells presenting 
both Her2 and MAGE-A3 while sparing cells with either single antigen alone (Figures 
2.2D and 2.2E).      
The synNotchàTCR AND gate design is highly versatile, and we demonstrated 
that it could be used with several other clinically important TCRs. As shown in Fig. 
2.8B, we constructed two other synNotchàTCR circuits: a-GFP synNotchàa-MART1 
TCR  and a-GFP synNotchàa-NY-ESO1 TCR (both using surface expressed GFP as a 
priming antigen). Jurkat T cells expressing these circuits only showed activation when 
stimulated with target cells presenting the appropriate pair of cognate ligands. We also 
showed that these circuits function in CD4+ human primary T cells (Fig. 2.8C). 
Together, these results suggest that synNotchàTCR circuits are a flexible system for 
engineering AND gate T cells to target externalàinternal antigen pairs.  
 
synNotch receptors can be engineered to recognize tumor-associated 
peptide:MHC complexes 
To enable further access to the intracellular antigen pool, we built synNotch 
receptors that can detect internal antigens (hereafter referred to as “inNotch” receptors).  
inNotch receptors have extracellular binding domains that are engineered to recognize 
specific pMHC complexes. SynNotch receptors can drive antigen-induced expression of 
any genetically encodable payload, so the main limitation to their input/output 
programmability has been their prior confinement to recognition of external cell surface 
antigens. Previous studies have shown that one can engineer antibodies that recognize 
specific pMHC antigens (Andersen et al., 1996; Chames et al., 2000; Dao et al., 2013; 
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Lev et al.). One example is a single chain antibody (scFv) that has been engineered to 
recognize the peptide FMNKFIYEI (158-166) derived from liver cancer antigen alpha-
fetoprotein (AFP) in complex with HLA-A2 (Liu et al., 2017). Here we designed an a-
AFP inNotch receptor by using this scFv as a synNotch receptor recognition domain.  
We first engineered human primary CD8+ T cells with an a-AFP inNotch receptor 
and a corresponding response element encoding an inducible BFP reporter (Figure 
2.3A). These T cells were then co-cultured with T2 target cells presenting varied levels 
of cognate AFP peptide, or an off-target WT1 peptide. The a-AFP inNotch T cells only 
activated BFP reporter expression in the presence of target cells presenting AFP, and 
reporter activity rose with increasing levels of target antigen (Figure 2.3B). These 
inNotch CD8+ T cells also induced BFP reporter expression in response to target K562 
myelogenous leukemia cells engineered to express both full AFP protein and HLA-A2, 
but not in response to control K562 cells expressing only HLA-A2 (Figure 2.3C). The a-
AFP inNotch receptor also functions in CD4+ T cells, suggesting that this inNotch 
receptor functions in a CD8 co-receptor-independent manner (Figures 2.9A and 2.9B). 
These experiments show that it is possible to engineer inNotch receptors to target 
internal antigens via sensing of pMHCs. This approach to recognizing intracellular 
proteins should enable synNotch T cells to target a greatly increased antigen pool. 
 
Internal-internal and internal-external antigen recognition AND gate circuits 
harnessing inNotch receptors 
After demonstrating that inNotch receptors could target intracellular antigens, we 
then tested whether these receptors could be incorporated into AND gates by regulating 
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either CAR or TCR expression. To construct a prototype internalàexternal dual 
antigen AND gate, we engineered human primary CD8+ T cells with an a-AFP inNotch 
receptor (internal antigen) driving inducible expression of an a-Her2 CAR (external 
antigen) (Figure 2.3D). These inNotchàCAR T cells showed robust AND gate 
behavior, selectively killing target T2 cells presenting both AFP and Her2, and not cells 
with either antigen alone (Figures 2.3E and 2.3F). To test the versatility of this 
approach for targeting different antigens, we engineered Jurkat T cells with an scFv-
based a-WT1 inNotch receptor (internal antigen;126-134 peptide presented by HLA-A2) 
(Zhao et al., 2015) driving inducible expression of a-Her2 CAR (external antigen) 
(Figure 2.9C). When co-cultured with T2 target cells, these Jurkat T cells were 
selectively activated by target cells presenting both WT1 and Her2, as measured by 
upregulation of CD69 (Figure 2.9D). 
Next, we tested whether inNotch receptors could be used to control TCR 
expression to program internalàinternal dual antigen AND gate T cells. We 
engineered human primary CD8+ T cells with an a-AFP inNotch receptor (internal 
antigen) driving inducible expression of an a-NY-ESO1 TCR (internal antigen) (Figure 
2.3G).  These inNotchàTCR T cells showed robust AND gate behavior, selectively 
killing target cells presenting both AFP and NY-ESO1, and not cells presenting either 
individual antigen (Figures 2.3H and 2.3I). To demonstrate the modularity of the 
inNotch/TCR circuit, we also engineered human primary CD8+ T cells with an a-WT1 
inNotch receptor (internal antigen) driving expression of an inducible a-NY-ESO1 TCR 
(internal antigen) (Figure 2.9E). These T cells also displayed AND gated activation, 
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selectively killing target cells presenting both WT1 and NY-ESO1 (Figures 2.9F and 
2.9G).   
These results show that it is now possible to incorporate one or two internal 
antigens into dual antigen AND gate circuits. This increased ability to tailor T cells to 
detect the intracellular antigen pool in different ways should yield powerful new 
examples of combinatorial antigen recognition of cancer and other disease tissues.  
 
Engineering three input AND gate circuit using multiple synNotch receptors in the 
same T cell to control expression of a split CAR 
To further improve cancer targeting precision, we wanted to design synNotch T 
cells that could extend AND gate sensing from 2 to 3-inputs. Bioinformatic analysis 
(companion manuscript from VanderSluis et al.) indicates that circuits that can detect 2-
3 antigen combinations should be very helpful in dramatically increasing the precision of 
tumor recognition for many cancers. To build a system requiring recognition of three 
independent antigen inputs to trigger T cell activation, we sought to use two different 
synNotch receptors to drive the components of a split CAR. For this strategy, we 
required two orthogonal synNotch systems that could function together in the same T 
cell. We therefore developed compatible synNotch platforms that utilize distinct 
intracellular transcriptional domains to regulate independent transcriptional programs. 
We engineered an a-Her2 Gal4-VP64 synNotch and an a-GFP LexA-VP64 synNotch, 
controlling expression of BFP and mCherry reporters, respectively (Figure 2.10A). We 
then co-cultured human primary CD4+ T cells containing these double synNotch 
receptors with K562 target cells expressing GFP, Her2, GFP/Her2, or neither antigen. 
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Reporter protein expression showed that the two synNotch receptors were able to 
generate robust independent responses with no crosstalk (Figures 2.10B and 2.10C).  
To then build a 3-input AND gate, we reasoned that we could use the multiple 
orthogonal synNotch receptors to control expression of both halves of a split CAR – only 
when both parts of the split CAR were induced would one observe killing based on 
recognition of the CAR antigen. In this case, two synNotch priming antigens and the 
third CAR antigen would be required for killing. Various two-part CAR systems have 
been developed in which recognition and signaling components are split into two 
molecules (Kim et al.; Tamada et al., 2012; Wu et al., 2015). For example, one group 
developed a CAR that recognizes a peptide neo-epitope (PNE) derived from the yeast 
transcription factor GCN4 (Rodgers et al., 2016). While normally inert, this CAR can be 
combined with a soluble adapter that contains the cognate PNE peptide fused to an 
scFv that targets an antigen of interest. The a-PNE CAR (here referred to as CARin) can 
only recognize target cells in the presence of a soluble adapter molecule (CARout) 
containing an antigen-binding domain (e.g. scFv) linked to the PNE tag.  
Here we used the a-PNE CAR system as a model split CAR that could be driven 
by two independent synNotch receptors. We made a secreted a-CD19 PNE-tagged 
adapter molecule (CARout) and first verified its ability to function in a simpler two input 
AND gate (Figures 2.10 E-G). To then generate a 3-input AND gate, we engineered 
human primary CD8+ T cells with both of the following synNotch circuits: a-Her2 
synNotch (Gal4-VP64)àa-CD19 PNE adapter (CARout) and a-GFP synNotch (LexA-
VP64)àa- PNE CAR (CARin) (Figures 2.4A and 2.4B). Since the engineered T cells 
should only express the CARin component in response to a-Her2 synNotch priming and 
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the CARout component in response to a-GFP synNotch priming, these T cells should 
only activate and kill target cells expressing all three antigens: GFP, Her2, and CD19 
(Figures 2.4C and 2.10D). Target cells expressing any antigen combination other than 
triple positive should be spared (Figure 2.4C).  
Indeed, these engineered T cells performed as expected and executed 3-antigen 
AND-gate recognition, selectively killing Her2/GFP/CD19 triple antigen positive K562s 
(Figures 2.4D and 2.4E). The ability to extend AND-gating from dual antigen to 3-input 
sensing will enable engineered T cells to attack much more tightly defined antigen 
signatures, improving their potential discrimination between cancer and healthy cells.  
 
Three input AND and NOT gate circuit that incorporates an apoptotic override 
response to integrate both positive and negative regulation 
Ideally, we would like to combine both positive and negative selection in tumor 
recognition. Both bioinformatic analysis and clinical experience indicate that NOT gate 
negative selection could help to significantly avert on-target off-tumor toxic T cell 
reactions with healthy tissues. For example, NOT gates could help eliminate deadly on-
target off-tumor cross-reactions that occurred during trials with engineered T cells 
targeting antigens such as Her2 or MAGE-A3. Bioinformatic analysis of antigen 
expression patterns in healthy tissues is beginning to reveal tissue-specific antigens 
(personal communication, Olga Troyanskaya) that could be used in NOT gates to 
prevent toxicities to tissues known to also express tumor-associated CAR or TCR 
antigens. Earlier work showed that an inhibitory CAR (iCAR) with inhibitory intracellular 
regulatory motifs could be used to construct NOT gates in therapeutic T cells (Fedorov 
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et al., 2013). It is unclear, however, how well the iCAR can function to directly override 
signaling of all possible types of CARs and TCRs. Thus, we sought to design a more 
flexible and robust NOT gate module that functions independently of CAR/TCR 
signaling. Here we show that we can engineer a novel synNotch-controlled apoptotic 
NOT gate, and that this NOT gate can be incorporated into higher order T cell 
recognition circuits that combine both positive and negative antigen selection.   
We designed a modular NOT control switch in which a synNotch receptor 
induces an apoptotic response that more globally overrides T cell activation (referred to 
here as “offNotch circuit”). We predicted that synNotch could be used to initiate antigen-
dependent T cell apoptosis by driving expression of the pro-apoptotic protein fragment 
truncated Bid (tBID). BID is a member of the Bcl-2 protein family whose cleavage by 
caspase-8 releases tBID; tBID then translocates to the mitochondria to initiate apoptosis 
(Wei et al., 2000). To test the ability of synNotch-induced tBID expression to drive 
apoptosis, we engineered human primary CD8+ T cells with an a-Her2 Gal4-VP64 
synNotch controlling tBID expression (Figure 2.11A). We found that these offNotch T 
cells selectively die in the presence of Her2 expressing K562 target cells, demonstrating 
that synNotch-induced tBID expression can drive T cell death (Figure 2.11B).  
We then tested whether offNotch-induced apoptosis could act as a NOT gate 
when integrated into a higher order AND gate with 3-input antigen recognition circuit 
(Figure 2.5A). A critical component of a therapeutic T cell response is the explosive 
cytokine-driven cell proliferation that results from initial activation. We reasoned that if a 
NOT input induced apoptosis, then the T cells might be locally blocked from undergoing 
this critical expansion. We engineered human primary CD8+ T cells with a composite 
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circuit: for negative selection, the cells contained an a-Her2 offNotch circuit (driving tBID 
expression); for positive selection, the cells contained a two input AND gate -- a-GFP 
LexA-VP64 synNotch controlling expression of the a-CD19 CAR (Figure 2.5B). Based 
on prior experience with this AND gate module, we knew that these T cells should 
activate and kill only target cells expressing both GFP and CD19. We wanted to test 
whether a-Her2 offNotch-driven tBID expression could then override this AND gate to 
prevent killing of Her2/GFP/CD19 triple antigen positive cells (i.e. does Her2 act as an 
overriding negative input). 
To test this positive/negative 3 input gating circuit, we performed a timecourse 
co-culturing these engineered T cells with K562 target cells expressing either CD19, 
Her2/CD19, GFP/CD19, or Her2/GFP/CD19. We found that after 24 hours there was 
largely selective killing of GFP/CD19 positive cells, with some minor killing of 
Her2/GFP/CD19 positive cells (Figure 2.5C). When we continued the assays from 24 to 
96 hours, however, the engineered T cells continued to kill GFP/CD19 positive cells, but 
stopped killing Her2/GFP/CD19 positive cells as shown by the flat line of target cell 
survival (Figures 2.5C and 2.11C). Thus, activation of the new NOT module indeed led 
to sustained blocking of T cell killing.  
To more precisely monitor the effect of offNotch-driven tBID expression on the 
engineered T cells, we measured T cell population expansion and single cell 
proliferation at the end of the co-cultures. Engineered CD8+ T cells were found to 
selectively expand and proliferate in the presence of GFP/CD19 positive cells, while T 
cell expansion was blocked in the presence of Her2/GFP/CD19 positive cells (Figures 
2.5D and 2.5E). Thus, the addition of the Her2 input (detected by the offNotch circuit) 
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was sufficient to block proliferation.  Human primary CD4+ T cells engineered with this 
same circuit showed a similar pattern of input regulation (Figures 2.11D and 2.11E).  
These results show that the offNotch NOT module (synNotch à tBID apoptotic 
inducer) can block T cell expansion and survival that is essential for a strong T cell 
response, and that this system can be modularly incorporated into combinatorial antigen 
recognition circuits that include both positive and negative antigen selection. The ability 
to incorporate this type of modular negative regulation on a therapeutic T cell provides 
powerful new tools for shaping the types of antigen patterns that can be recognized and 
discriminated against. 
 
Dual-recognition synNotch receptors allow engineering of different types of OR-
AND circuits that balance precision and flexibility in recognition 
While increased selectivity, either through positive or negative selection, is 
important to avoid normal tissue cross-reactivity, decreasing selectivity can be 
advantageous in the context of tackling the challenges of tumor antigen heterogeneity 
and escape.  Prior work has shown that OR gate receptors – e.g. CAR’s that have dual 
antigen recognition heads and can activate in response to either of two target antigens 
– can help to overcome tumor heterogeneity and to minimize the probability of tumor 
resistance by target antigen loss (Fry et al., 2017; Grada et al., 2013; Hegde et al., 
2016; Zah et al., 2016). One concern with engineering increasingly precise 
combinatorial antigen sensing T cells is that there is an increased risk of treatment 
failure due to antigen heterogeneity or escape. If T cells are engineered to target too 
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limited of an antigen signature, then added safety will be at the expense of loss of 
efficacy due to incomplete killing of a heterogeneous cancer cell population.  
This trade-off between too much and too little selectivity, however, could in 
principle be overcome by incorporating AND and OR capabilities into composite higher 
order gating circuits. In other unpublished studies from our lab, we have programmed T 
cells with a three-input circuit in which a single antigen synNotch drives expression of 
an OR gate CAR (circuit: if detect antigen A, then kill based on antigens B or C) and 
found that these T cells markedly improve treatment of heterogeneous glioblastoma 
tumors in mice by addressing the dual problems of antigen specificity and 
heterogeneity. Here, we asked if we could engineer a three-input circuit in which an OR 
gate synNotch could drive expression of a CAR (circuit: if detect antigens A or B, then 
kill based on antigen C) (Figures 2.6A and 2.6B). The ability to detect two antigens 
with an OR gate synNotch would be extremely helpful for targeting tumors with sparse, 
heterogeneous expression of two tumor-specific priming antigens. However, in prior 
work, synNotch receptors have only been engineered to respond to a single antigen. 
We reasoned that OR gate synNotch receptors could be constructed by 
incorporating two recognition domains targeting different antigens in tandem on a single 
synNotch receptor, as long as each individual antigen could still yield activation. As a 
proof-of-principle, we designed an a-GFP/Her2 dual synNotch utilizing a tandem 
recognition module made up of a N-terminal a-GFP nanobody and a-Her2 scFv.  We 
screened several different length flexible linkers between the two recognition domains. 
We then compared human primary CD4+ T cells expressing synNotch receptors either 
targeting GFP alone, Her2 alone, or dual-antigen GFP or Her2 (Figure 2.6C). The a-
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GFP/Her2 dual synNotch T cells robustly responded to either GFP positive or Her2 
positive target cells (as well as double positive cells), inducing expression of the BFP 
reporter at similar levels to that observed in T cells with either of the single antigen 
synNotch receptors (Figure 2.6C). These results indicate that dual recognition 
synNotch receptors (OR synNotch receptors) can be engineered to retain the specificity 
and strength of their component individual binding domains, and thus provide new 
opportunities to build circuits with diversified capabilities to combat antigen 
heterogeneity and escape. 
We then tested the concept of using a dual synNotch receptor to control 
expression of a CAR in a 3-input circuit with OR gate priming (Figure 2.6A). We 
engineered human primary CD8+ T cells with an a-GFP/Her2 dual synNotch controlling 
expression of an a-CD19 CAR (Figure 2.6B). Integrating the dual synNotch with the 
inducible CAR should increase the specificity of killing relative to constitutive CAR 
expression, while providing the flexibility to maintain on-target activity in the face of 
synNotch antigen heterogeneity or escape. The 3-input ORàAND T cells only killed 
CD19 positive K562 target cells that also co-expressed GFP or Her2, sparing CD19 
only target cells (Figures 2.6D and 2.12A-C). In summary, we demonstrate the ability 
to engineer three-input gates that incorporate the precision of AND gates with the 
flexibility of OR gates. This class of circuits should enable engineered T cells to balance 
targeting precision with flexibility, thus allowing the detection of tumor-specific multi-
antigen signatures, even in the case of trying to capture a more heterogeneous cancer 
cell population. Our lab has performed further studies of this of this type in which 
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ANDàOR three-antigen circuits are used to target heterogeneous glioblastoma 
(unpublished work). 
  
 
DISCUSSION 
 
Developing precision cell therapies that can harness cancer informatics 
Bioinformatic analysis by our collaborators demonstrates that targeting 
combinations of 2-3 antigen signatures using Boolean logic will dramatically improve the 
potential discrimination between tumor cells and healthy cells. Traditional small 
molecule and protein therapeutics are generally poorly suited to distinguish cancer cells 
based on combinatorial molecular features. Cells, however, with their ability to integrate 
signals in highly non-linear ways, are ideally suited for such detection.  Here we 
demonstrate the ability to engineer therapeutic T cells with advanced combinatorial 
antigen recognition capabilities – we have designed a suite of recognition circuits that 
can cover and match the diverse set of possible multi-antigen targeting opportunities 
that are presented by tumors. We utilized the customizability and modularity of the 
synNotch receptor platform, combined with TCRs, CARs and split CARs to engineer T 
cells with circuits targeting up to 3 antigens in diverse combinatorial ways. These 
antigen inputs can be integrated through AND, NOT or OR logic, allowing customized 
sculpting of the antigen space to best isolate the cancer cells for recognition. This kind 
of increased recognition capability is likely to be critical if we are to engineer therapeutic 
T cells that can safely treat many solid cancers. 
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These advanced T cell recognition circuits provide a new way to harness cancer 
and healthy tissue gene expression data as part of the design pipeline for cell therapies. 
Up to this point, gene expression signatures have primarily been used to stratify 
patients and predict correlated responsiveness to treatments; we have lacked the 
capability and platform to directly exploit unique expression signatures as targets of 
therapeutic recognition. The multi-antigen recognition circuits described here now 
enable engineering therapeutic cells that can be designed to recognize particularly 
informative and discriminatory antigen expression signatures, like those identified our 
bioinformatic collaborators. 
 
Periodic table of multi-antigen pattern recognition circuit designs 
There are finite ways in which a combination of antigens can be distinctly 
recognized.  As summarized in Figure 1, extracellular or intracellular antigens can be 
recognized by CARs and TCRs, respectively. Pairs of these specific individual antigens 
could provide increased recognition information through a finite number of combinatorial 
relationships: AND (positive), NOT (negative), or OR (union) logic.  Thus, although the 
specific high-information content antigens will differ for each cancer, it is likely that there 
are a fairly limited number of canonical recognition scenarios that could be used to 
optimize cancer vs normal tissue discrimination. Here, we enumerate these possible 
recognition scenarios and show that we can engineer or design T cell circuits that can 
achieve all of these core classes of recognition (summarized in Figure 2.7).  We limit 
ourselves to recognition of 1 to 3 antigens, although similar design logic could, in 
principle, be extended to engineer circuits that recognize a higher number of antigens. 
	 71	
The circuits we have designed here, thus, represent a type of “periodic table” of core 
multi-antigen recognition circuit designs that we can use as the starting template for 
engineering of new T cell therapies for any cancer. 
First, we consider the general situation in which a dual antigen combination can 
discriminate a cancer from all normal tissues (2nd row of diagram in Fig. 7). Here there 
are three major possible recognition schemes: 1) A and B (2AND) – the antigen 
combination is only present in the tumor), 2) A and NOT B (2NOT) – antigen A is in tumor 
and some normal tissues, but these cross-reactive normal tissues also express antigen 
B (note: A OR B represents a third possible logic circuit, but this circuit is generally 
thought to be useful for overcoming tumor heterogeneity, i.e. situations where you need 
to recognize A or B to capture all tumor cells; this circuit, however, will have the problem 
of higher, additive cross-reactivity, which will be discussed below). These dual antigen 
recognition opportunities can be recognized by several possible circuits. A 
synNotchàCAR circuit can achieve strong 2AND recognition (Roybal et al., 2016a). 2NOT 
recognition can be achieved either using a CAR + inhibitory CAR (iCAR) circuit 
(Fedorov et al., 2013) or by combining a CAR with the offNotch circuit, as developed 
here.  Furthermore, we show here that we can dramatically expand the recognition 
range of 2AND recognition circuits, by incorporating recognition of combinations of 
different internal and external antigens (2ANDout-out; 2ANDout-in, 2ANDin-out, 2ANDin-in) by using 
different combinations of receptors types - CARs, synNotch’s, and TCRs - for antigen 
detection.  The ability to harness both intracellular and surface antigens in combinatorial 
recognition dramatically increases the space of possible antigens that can be 
considered for targeting (with the caveat that TCR and inNotch receptor recognition will 
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be HLA restricted). Note that we predict that it is also possible to engineer different 
types of 2NOT circuits that incorporate both intracellular and extracellular antigens, but 
these were not explored here (see Figure 2.7) 
There is a larger number of possible recognition classes for 3 antigen signatures, 
shown in the third row of Fig. 2.7. The simultaneous co-expression of three different 
antigens in a tumor can be recognized by the 3AND circuit (see Fig. 4), while the 
presence of two antigens and the simultaneous absence of a third antigen can be 
recognized by the 3AND-NOT circuit (design and data in Fig. 5). As shown in the 3D 
antigen space graphs at the bottom of Fig. 2.7, these two 3-input circuits are ideal for 
recognizing a tightly defined sector of antigen space, through a combination of either 
positive or negative selection.   
It is also possible to incorporate OR functionality into 3-input circuits to capture 
cancers that have antigen heterogeneity. In cases of heterogeneity (i.e. cancer 
expressing antigens A or B), an A OR B logic circuit can be used to fully encompass the 
cancer cell population, for example, by using a tandem CAR that recognized two 
antigens.  But, the tradeoff of the OR gate, is that it also has the potential to significantly 
increase any normal cell cross-reactivity, since cross reactions will be additive. Thus, it 
can be extremely useful to deploy 3-input gates that incorporate both AND and OR 
relationships. Here we have built a 3OR-AND circuit that uses a dual synNotch to drive 
expression of a CAR to recognize antigen combination (A or B) and C. Conversely, we 
can also design a circuit in which a synNotch receptor drives expression of a tandem 
CAR, thereby yielding recognition of the antigen combination A and (B or C), a T cell 
circuit that we have constructed and used to target glioblastoma in unpublished work by 
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our lab. The 3-input circuits that incorporate OR and AND logic allow one to identify and 
take advantage of those dimensions of antigen space that can be surgically carved for 
specificity, while dealing more flexibly with those dimensions of antigen space that need 
to remain broader in order to sufficiently capture the entire cancer cell population. 
Furthermore, although we have not built it here, it is trivial to design a 4[OR]AND[OR] circuit 
(recognition signature: [A or B] and [C or D]) by using a dual synNotch receptor to 
control expression of a dual CAR.  Note that we have also not constructed a 3NOTNOT 
circuits (recognition signature: A NOT B NOT C), but there are obvious ways to 
construct this, such as by combining a CAR with two iCARs, two offNotch subcircuits, or 
dual-recognition versions of either inhibitory receptor. 
Thus, the set of advanced circuits described and validated here should allow one 
to carve antigen space in more distinct ways to find the optimum recognition sector(s) to 
capture most cancers while minimizing normal tissue cross-reactivity. This essentially 
complete set of circuit designs can be used as a starting point to recognize almost any 
possible class of 2 or 3 antigen signatures.  
 
A novel cell death controlled NOT gate.  
A key new aspect of this work involves the design of a new modular NOT gate 
that can be flexibly incorporated into diverse multi-antigen pattern recognition circuits. 
This work shows the power of negative selection in achieving tumor recognition 
specificity. To construct a robust and flexible NOT gate, we focused on linking antigen 
inputs to control of cell death/proliferation – a global level of control that is critical for a 
therapeutic response. Here we have used synNotch receptors to control expression of 
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the apoptotic activator tBID. By acting at the level of apoptosis/proliferation this type of 
NOT gate should be able to globally override most forms of T cell activation more 
robustly than NOT gates that act on particular steps of T cell activation. 
 
Promises and challenges of targeting solid cancers 
There remain several major challenges to using engineered therapeutic T cells to 
treat solid cancers. First and foremost, we must be able to develop ways to specifically 
recognize the tumors without the potentially deadly cross-recognition of normal tissues.  
In addition, we must be able to engineer the cells to traffic to the tumors, to persist and 
proliferate, and to overcome local immune suppression. Here we provide an approach 
and toolkit to significantly increase our ability to solve the solid tumor recognition 
problem.  
Together with unpublished bioinformatic analysis of antigen expression patterns 
in tumors versus healthy tissues, this work provides a roadmap for combining 
bioinformatics and synthetic biology to engineer therapeutic T cells that can achieve 
pinpoint recognition of target disease cells, via recognition of almost any class of multi-
antigen pattern. The versatility and modularity of the types of receptors that are now 
available to engineer T cells allows one to generate a circuit that fits nearly any type of 
combinatorial recognition opportunity that is identified computationally. In other 
unpublished work, we show how this type of approach could be used to address the 
major unmet needs in therapeutic T cell treatment of glioblastoma, in particular to 
design effective combinatorial antigen recognition circuits that balance the specificity 
needed for discrimination with the flexibility needed to overcome tumor heterogeneity.   
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METHODS 
 
Source of Primary Human T cells 
Blood was obtained from Blood Centers of the Pacific (San Francisco, CA) as 
approved by the University Institutional Review Board. Primary CD4+ and CD8+ T cells 
were isolated from anonymous donor blood after apheresis. 
 
Construct Design 
All synNotch receptors used in this study were built using the mouse Notch1 
(NM_008714) minimal regulatory region (Ile1427 to Arg 1752). The following binding 
domains were engineered into synNotch receptors: a-CD19 scFv clone FMC63 (Grupp 
et al., 2013), a-Her2 scFv clone 4D5-8 (Liu et al., 2015), a-GFP nanobody clone LaG17 
(Fridy et al., 2014), a-HLA-A2/AFP158-166 scFv clone ET1402L1 (Liu et al., 2017), or a-
HLA-A2/WT1126-134 scFv clone S3.3 (Zhao et al., 2015). synNotch receptors were 
designed to include either Gal4 DNA-binding domain (DBD) VP64 or LexA DBD VP64 
fusion proteins as a synthetic transcription factor. All synNotch receptors contain an N-
terminal CD8a signal peptide (MALPVTALLLPLALLLHAARP) for membrane targeting. 
Following the CD8a signal peptide, Gal4 synNotch receptors contain a myc tag 
(EQKLISEEDL) and LexA synNotch receptors contain a FLAG tag (DYKDDDDK) for 
easy and orthogonal surface detection with a-myc AF647 (Cell Signaling #2233) and a-
FLAG AF488 (R&D Systems #IC8529G), respectively.  
All CARs used in this study were designed by fusing scFvs to the human CD8a 
chain hinge and transmembrane domains and the cytoplasmic regions of the human 4-
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1BB and CD3z signaling proteins. The following binding domains were engineered into 
CARs: a-CD19 scFv clone FMC63 (Grupp et al., 2013), a-Her2 scFv clone 4D5-8 (Liu 
et al., 2015), a-GCN4 (PNE) scFv clone 52SR4 (Zahnd et al., 2004).  a-CD19 and a-
Her2 CARs included an N-terminal myc tag for easy detection with a-myc AF647 (Cell 
Signaling #2233), while the a-GCN4 (PNE) CAR was detected using a PNE-FITC 
peptide conjugate (custom from Genscript).  All CARs contain an N-terminal CD8a 
signal peptide. 
All TCRs used in this study were constructed in a multicistronic configuration with 
T2A peptides enabling 1:1 stoichiometric expression of the TCR chains. The sequences 
of the following TCRs were used: a-HLA-A2/MAGE-A3 TCR (Chinnasamy et al., 2011), 
a-HLA-A2/NY-ESO1 TCR 1G4 a95LY clone (Robbins et al., 2008), a-HLA-A2/MART1 
TCR  DMF5 clone (Johnson et al., 2006). The MAGE-A3 TCR was cloned in an a-T2A-
b configuration, and the NY-ESO1 and MART1 TCRs were cloned in a b-T2A-a 
configuration. 
For experiments with T cells expressing a single synNotch receptor the Gal4 
system was utilized, and the receptors were cloned into a modified pHR’SIN:CSW 
vector containing a constitutive SFFV or PGK promoter. For these experiments, the 
pHR’SIN:CSW vector was also modified to make the response element plasmids. Five 
copies of the Gal4 DNA binding domain target sequence 
(GGAGCACTGTCCTCCGAACG) were cloned 5’ to a minimal CMV promoter. Also 
included in the response element plasmids is a PGK promoter that constitutively drives 
mCherry or BFP expression to easily identify transduced T cells. For all synNotch 
response element vectors, the inducible transgene (e.x. CAR or TCR) was cloned via a 
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BamHI site in the multiple cloning site 3’ to the Gal4 response elements. All constructs 
were cloned via InFusion Cloning (Takara Bio #638910). 
For experiments with T cells expressing two synNotch receptors, single vector 
constructs were designed to contain a synNotch receptor and its corresponding 
response element. For these experiments, the pHR’SIN:CSW vector was modified to 
include both a constitutively expressed synNotch receptor as well as the corresponding 
response element. The Gal4 response element was designed as described above. For 
the LexA response element, 7 copies of the LexA DNA binding domain target sequence 
(CTGTATATACTCACAG) were cloned 5’ to a minimal CMV promoter. The sequence 
for the LexA repeat binding motif was obtained from (Ottoz et al., 2014). The inducible 
transgene (e.x. CAR or TCR) was cloned via a BamHI site in the multiple cloning site 3’ 
to the Gal4 or LexA response elements. The constitutively expressed synNotch receptor 
was expressed from a PGK constitutive promoter 3’ to the inducible transgene. 
synNotch receptors were cloned via a NdeI site in the multiple cloning site 3’ PGK 
promoter.  
 
Primary Human T Cell Isolation and Culture 
Primary CD4+ and CD8+ T cells were isolated from anonymous donor blood 
after apheresis by negative selection (STEMCELL Technologies #15062 and 15023). T 
cells were cryopreserved in RPMI-1640 (Corning #10-040-CV) with 20% human AB 
serum (Valley Biomedical, #HP1022) and 5% DMSO. After thawing, T cells were 
cultured in human T cell medium consisting of X-VIVO 15 (Lonza #04-418Q), 5% 
Human AB serum and 10 mM neutralized N-acetyl L-Cysteine (Sigma-Aldrich #A9165) 
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supplemented with 30 units/ mL IL-2 (NCI BRB Preclinical Repository) for all 
experiments.  
 
Lentiviral Transduction of Human T Cells and Target cells 
Lenti-X 293T packaging cells (Clontech #11131D) were cultured in medium 
consisting of Dulbecco’s Modified Eagle Medium (DMEM) (Gibco #10569-010), 10% 
fetal bovine serum (FBS) (Univeristy of California, San Francisco [UCSF] Cell Culture 
Facility), and gentamicin (UCSF Cell Culture Facility). Fresh packaging cells were 
thawed after cultured cells reached passage 30.  
Pantropic VSV-G pseudotyped lentivirus was produced via transfection of Lenti-X 
293T cells with a pHR’SIN:CSW transgene expression vector and the viral packaging 
plasmids pCMVdR8.91 and pMD2.G using Fugene HD (Promega #E2312). Primary T 
cells were thawed the same day, and after 24 hr in culture, were stimulated with 
Dynabeads Human T-Activator CD3/CD28 (Thermo Scientific #11131D) at a 1:3 
cell:bead ratio. At 48 hr, viral supernatant was harvested and the primary T cells were 
exposed to the virus for 24 hr. At day 5 post T cell stimulation, Dynabeads were 
removed and the T cells expanded until day 12 when they were rested and could be 
used in assays. T cells were sorted for assays with a FACs ARIA II on day 5 or 6 post T 
cell stimulation.  
 
Jurkat T Cells  
Two different Jurkat T cell lines were used in this study: parental E6-1 Jurkat T 
cells (ATCC #TIB-152) and J.RT3-T3.5 Jurkat T cells (ATCC #TIB-153), which is a 
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mutant line derived from the E6-1 clone. J.RT3-T3.5 Jurkats lack the beta chain of the 
TCR, and as a result do not express native CD3 or TCR alpha/beta heterodimer on their 
surface. Both Jurkat cell lines were cultured in medium consisting of RPMI-1640 
(Corning #10-040-CV), 10% FBS, penicillin and streptomycin (UCSF Cell Culture 
Facility), and GlutaMAX (Thermo Scientific #35050061). Jurkat T cells transduced with 
synNotch circuits were sorted for assays with a FACs ARIA II. 
 
Cancer Cell Lines 
The cancer cell lines used were K562 myelogenous leukemia cells (ATCC #CCL-
243) and T2 lymphoblastoid cells (ATCC #CCL-1992). K562s were cultured in medium 
consisting of Iscove’s DMEM (Corning #10-016-CV), 10% FBS, and gentamicin. T2s 
were cultured in medium consisting of Iscove’s DMEM supplemented with 20% FBS.  
K562s and T2s were lentivirally transduced to expressed all external antigens. K562s 
were also lentivirally transduced to express internal/secreted protein AFP. All external 
antigens were expressed as fusion proteins of their extracellular domains fused to the 
PDGFR transmembrane domain (for the case of GFP, the entire GFP was fusion to the 
PDGFR transmembrane domain). The one external protein expressed with its native 
transmembrane domain was HLA-A2 in K562s. Within the exception of GFP whose 
fluorescence was directly observed, antigen levels were determined via flow cytometry 
after staining cells with the following antibodies: a-Her2 APC (Biolegend #324408), a-
CD19 BV421 (Biolegend #302234), or a-HLA-A2 APC (Biolegend #343308). All cell 
lines were sorted via FACS for expression of the antigen transgenes. Cells transduced 
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with different combinations of antigens were sorted with a FACS ARIA II for consistent 
expression levels of each individual antigen across different target cell lines.   
 
Peptides 
All antigen peptides used in this study are HLA-A2-restricted. Synthetic peptides 
corresponding to cancer antigens were obtained from one of two sources. Peptides for 
MAGE-A3112-120 (KVAELVHFL), AFP158-166 (FMNKFIYEI), WT1126-134 (RMFPNAPYL) 
were custom synthesized by GenScript. Peptides for NY-ESO1157-165 (SLLMWITQV) 
(AnaSpec #AS-63823) and MART126-35 (EAAGIGILTV) (Anaspec #AS-61011) were 
ordered from AnaSpec. Purity of peptides was verified at >98% by mass spectrometry 
performed by peptide supplier. Upon delivery, peptides were dissolved in 
dimethylsulfoxide (DMSO) at 2 mM and stored at -20°C until use. For assays, peptides 
were thawed and serially-diluted in T2 cell medium.  
 
T2 Cell Peptide Pulsing  
One to two million T2 cells were pulsed at a concentration of 10 million cells/mL 
in T2 cell media. T2 cells were pulsed with each peptide for 2 hours at 37°C in wells of a 
96-well round bottom plate. T2 cells were then diluted in T cell medium to the desired 
cell concentration for use in co-culture T cell assays. Unless indicated otherwise, T2s 
were pulsed with inNotch target antigen peptides at 10 µM and TCR target antigen 
peptides at 10 nM. 
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In Vitro Stimulation of synNotch T cells 
For all in vitro synNotch T cell assays (including both reporter and killing assays), 
5x104 T cells were co-cultured with target cells at a 1:1 ratio. The Countess II Cell 
Counter (ThermoFisher) was used to determine cell counts for all assay set up. T cells 
and target cells were mixed in round bottom 96-well tissue culture plates in 200 µL T 
cell media, and then plates were centrifuged for 1 min at 400 x g to initiate interaction of 
the cells. Cells were co-cultured for anywhere from 18 to 96 hours before analysis via 
flow cytometry with a BD LSR II.  
 
Antibody Staining and Flow Cytometry Analysis  
All antibody staining for flow cytometry was carried out in wells of round bottom 
96-well tissue culture plates. Cells were pelleted by centrifugation of plates for 4 min at 
400 x g. Supernatant was removed and cells were resuspended in 50 µL PBS 
containing the fluorescent antibody of interest. Cells stained 25 minutes at 4°C in the 
dark. Stained cells were then washed two times with PBS and resuspended in fresh 
PBS for flow cytometry with a BD LSR II. All flow cytometry data analysis was 
performed in FlowJo software (TreeStar). 
 
Flow cytometry-based T Cell Cytotoxicity Assay 
For all cytotoxicity assays, synNotch T cells or untransduced T cells were co-
cultured with target cells at a 1:1 ratio as described above. After intended periods of 
incubation, samples were centrifuged for 4 min at 400 x g. Supernatant were then 
removed and cells were resuspended in PBS for flow cytometry with a BD LSR II. 
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Control samples containing only the target cells were used to set up flow cytometry 
gates for live target cells based on forward and side scatter patterns. For assays with 
K562 target cells, target cells were further gated on high mCherry fluorescence, as all 
K562 lines used in assays were engineered to express a cytoplasmic mCherry marker. 
For assays with T2 target cells, targets cells were gated on low CellTrace Violet dye 
(ThermoFisher #C34557) fluorescence, as T cells used in these assays were labeled 
with CellTrace Violet to enable clear differentiation of populations. The level of target 
cell survival was determined by comparing the fraction of target cells alive in the culture 
compared to treatment with untransduced T cell controls.  
 
Tracking of T Cell Proliferation  
Primary CD4+ or CD8+ synNotch T cells were labeled with CellTrace Violet 
following manufacturer’s instructions. synNotch T cells T cells were co-cultured with 
target cells at a 1:1 ratio as described above. After 96 hours, samples were centrifuged 
for 4 min at 400 x g prior to resuspension in fresh PBS for flow cytometry with a BD LSR 
II. For flow cytometry analysis, K562 target cells were excluded using a gate on high 
mCherry fluorescence, as all K562 lines used in assays were engineered to express a 
cytoplasmic mCherry marker. 
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Figure 2.1. Potential modes of combinatorial antigen recognition to increase T 
cell specificity for cancer cells 
 
T cells have the potential to be engineered to recognize diverse patterns of antigens 
expressed by cancer cells. Clinically approved CAR T cell therapies and the vast 
majority of engineered T cells in trials target a single antigen. Due to the rarity of truly 
cancer-specific single antigens, there have been various instances of ON-target OFF-
tumor reactivity with healthy tissues causing severe and sometimes fatal side effects. 
Several groups have tried to overcome this limitation by engineering T cells with dual 
antigen combinatorial recognition systems programming either AND gate, OR gate, or 
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NOT gate logic. While these strategies have improved T cell tumor recognition 
specificity, the combinatorial antigen sensing toolkit must be advanced to address 
various unmet cancer targeting needs. Here, we show that synNotch receptors are a 
versatile platform to engineer T cells with an array of novel combinatorial antigen 
recognition capabilities. Dual antigen AND gates were previously restricted to sensing 
only extracellular antigens. synNotch T cells can be engineered with dual antigen AND 
gates recognizing one or two intracellular antigens, which make up most the human 
proteome and an even greater percentage of the cancer antigen-ome. synNotch T cells 
can be engineered to sense combinations of up to 3 antigens, improving targeting 
specificity relative to previously sensing only 2 antigens. synNotch T cells with 3-input 
recognition circuits can also integrate multiple types of logic within the same program. 
Engineering synNotch T cells with this kind of computational power provides the ability 
kill target tumor cells with tremendous precision and programmability. 
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Figure 2.2. synNotch-driven TCR expression enables AND-gate human primary 
CD8 T cells to target antigen pairs that include peptide-MHC antigens 
 
(A) Design of a dual antigen AND gate circuit controlling T cell activation that 
recognizes an external-internal antigen pair: the a-Her2 Gal4-VP64 synNotch (external) 
induces expression of the a-MAGE-A3 TCR (internal, pMHC).  
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(B) Primary human CD8 T cells engineered with this circuit only express the a-MAGE-
A3 TCR in response to antigen binding by the constitutively expressed a-Her2 
synNotch. These T cells only activate in the presence of target cells expressing both 
Her2 and MAGE-A3, avoiding toxic reactions with healthy cells expressing either 
individual antigen. 
 
(C) Primary human CD8 T cells were engineered with the circuit shown in (B). The TCR 
induction construct contained a BFP reporter to monitor TCR expression. Histograms of 
BFP reporter expression level show that the a-MAGE-A3 TCR is only expressed in 
response to T2 target cells expressing Her2 (representative of at least 3 independent 
experiments). 
 
(D) Forward scatter and side scatter flow cytometry plots of 24 hour 1:1 E:T co-cultures 
between engineered CD8 T cells shown in (B) and T2 target cells presenting Her2 only, 
MAGE-A3 only, or both Her2 and MAGE-A3. T2 target cells fall within the indicated 
gate. The synNotch/TCR AND gate T cells specifically killed the dual-positive 
Her2/MAGE-A3+ T2 cells, as demonstrated by the selective reduction of cells in the T2 
gate (representative of at least 3 independent experiments). 
 
(E) Quantification of replicate target cell killing data shown in panel (D). (n=3, error bars 
are SD).  
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Figure 2.3. synNotch receptors can be engineered to recognize tumor-associated 
peptide-MHC antigens and control CAR/TCR expression in AND-gate CD8 T cells 
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(A) Primary human CD8 T cells were engineered to express an internal antigen-sensing 
synNotch (“inNotch”) targeting the cytosolic/secreted protein AFP and utilizing Gal4-
VP64 to control expression of a corresponding BFP reporter response element. The 
inNotch receptor’s antigen binding domain was built using an a-HLA-A2/AFP scFv 
specific for the HLA-A2 complexed FMNKFIYEI (158-166) peptide derived from AFP. 
 
(B) Engineered CD8 T cells shown in (A) were co-cultured at 1:1 E:T for 24 hours with 
T2 target cells pulsed with a titration of AFP158-166 peptide or off-target WT1 peptide. 
Histograms of BFP levels measured via flow cytometry show selective reporter 
induction in the presence of AFP, with increasing induction levels in response to 
increasing AFP peptide concentrations.  
 
(C) Engineered CD8 T cells shown in (A) were co-cultured at 1:1 E:T for 24 hours with 
K562 target cells expressing HLA-A2 only or both HLA-A2 and AFP. Histograms show 
selective induction of the inNotch BFP reporter in response AFP positive K562 target 
cells (representative of at least 3 independent experiments). 
 
(D) Design of a dual antigen AND gate circuit controlling T cell activation that 
recognizes an internal-external antigen pair: the a-AFP Gal4-VP64 inNotch (internal, 
pMHC) induces expression of the a-Her2 41BBz CAR (external). 
 
(E) Forward scatter and side scatter flow cytometry plots of 24 hour 1:1 E:T co-cultures 
between engineered CD8 T cells shown in (D) and T2 target cells presenting AFP only, 
Her2 only, or both AFP and Her2. T2 target cells fall within the indicated gate. The 
inNotch/CAR AND gate T cells specifically killed the dual-positive AFP/Her2+ T2 cells, 
as demonstrated by the selective reduction of cells in the T2 gate (representative of at 
least 3 independent experiments). 
 
(F) Quantification of replicate target cell killing data shown in panel (E). (n=3, error bars 
are SD). 
 
(G) Design of a dual antigen AND gate circuit controlling T cell activation that 
recognizes an internal-internal antigen pair: the a-AFP Gal4-VP64 inNotch (internal, 
pMHC) induces expression of the a-NY-ESO1 TCR (internal, pMHC). 
 
(H) Forward scatter and side scatter flow cytometry plots of 24 hour 1:1 E:T co-cultures 
between engineered CD8 T cells shown in (G) and T2 target cells presenting AFP only, 
NY-ESO1 only, or both AFP and NY-ESO1. T2 target cells fall within the indicated gate. 
The inNotch/TCR AND gate T cells specifically killed the dual-positive AFP/NY-ESO1+ 
T2 cells, as demonstrated by the selective reduction of cells in the T2 gate 
(representative of at least 3 independent experiments). 
 
(I) Quantification of replicate target cell killing data shown in panel (H). (n=3, error bars 
are SD). 
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Figure 2.4. Multiple synNotch receptors can be used within the same T cell to 
program 3-input AND-gate combinatorial antigen control over cancer cell killing 
 
(A) Design of a 3-input AND gate circuit controlling T cell activation: the orthogonal a-
Her2 synNotch and a-GFP synNotch each control expression of a different part of the 
a-CD19 split CAR. 
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(B) Diagram depicting 3-receptor circuit engineered in primary human CD8 T cells to 
generate a 3-input AND gate controlling T cell activation. Multiple orthogonal synNotch 
receptors are expressed in CD8 T cells, each controlling expression of a different part of 
a split CAR. The split CAR is made up of the a-PNE 41BBz CAR (CARin) and secreted 
a-CD19 scFv linked to the PNE peptide (CARout). The engineered CD8 T cells can 
recognize and kill CD19+ target cells only when both parts of the split CAR are 
expressed. The a-Her2 Gal4-VP64 synNotch controls expression of the CARin and the 
a-GFP LexA-VP64 synNotch controls expression of the CARout. 
 
(C) Primary human CD8 T cells engineered with this circuit only express the CARout in 
response to antigen binding by the constitutively expressed a-GFP LexA-VP64 
synNotch. These T cells only express the CARin in response to antigen binding by 
constitutively expressed a-Her2 Gal4-VP64 synNotch.  These T cells only activate in the 
presence of target cells expressing GFP and Her2 and CD19, avoiding toxic reactions 
with cells expressing either CD19 alone, GFP and CD19, or Her2 and CD19. 
 
(D) Forward scatter and side scatter flow cytometry plots of 24 hour 1:1 E:T co-cultures 
between engineered CD8 T cells shown in (B) and K562 target cells expressing 
different combinations of CD19, GFP, and Her2. K562 target cells fall within the 
indicated gate. The 3-input AND gate T cells specifically killed the triple-positive 
Her2/GFP/CD19+ K562 cells, as demonstrated by the selective reduction of cells in the 
K562 gate (representative of at least 3 independent experiments). 
 
(E) Quantification of replicate target cell killing data shown in panel (D). (n=3, error bars 
are SD). 
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Figure 2.5. synNotch receptors can be used to integrate both positive and 
negative regulation in 3-input combinatorial antigen recognition circuits 
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(A) Design of a 3-input circuit integrating an AND gate with a NOT gate to control T cell 
activation: the a-GFP synNotch induces expression of the a-CD19 41BBz CAR, and the 
orthogonal a-Her2 synNotch induces expression of pro-apoptosis protein tBID 
(offNotch). 
 
(B) Diagram depicting 3-receptor circuit engineered in primary human CD8 T cells to 
integrate both positive and negative regulation controlling T cell activation. These T cells 
must first bind GFP via the LexA-VP64 synNotch to induce the a-CD19 41BBz CAR, 
and should only activate and kill target cells if they sense both GFP and CD19. The T 
cells also express the a-Her2 Gal4-VP64 offNotch circuit that induces tBID expression 
and T cell apoptosis in response to Her2 antigen binding. offNotch-driven T cell 
apoptosis should deplete the effector T cell population and serve as an antigen-
dependent NOT gate to prevent target cell killing. 
 
(C) Quantification of replicate target cell killing data gathered via flow cytometry after 1:1 
E:T co-cultures of varied times between engineered CD8 T cells shown in (B) and K562 
target cells expressing different combinations of CD19, GFP, and Her2. While in the first 
24 hours the T cells kill some of the Her2/GFP/CD19+ off-target cells, there is no further 
killing at later time points. In contrast, the T cells continue to kill the GFP/CD19+ on-
target cells over the 96-hour time course (n=3, error bars are SD). 
 
(D) Quantification of T cell numbers via flow cytometry after 96 hours in the co-culture 
experiment described in (C). T cell counts show selective expansion when T cells were 
co-cultured with GFP/CD19+ target cells and NOT Her2/GFP/CD19+ target cells (n=3, 
error bars are SD). 
 
(E) Histograms of T cells stained with CellTrace Violet dye in the co-culture experiment 
described in (C) and processed via flow cytometry after 96 hours. The leftward shift of 
peaks in the histograms indicate T cell proliferation and dilution of the pre-labeled dye 
during increasing rounds of cell division. The T cells strongly proliferate only in the 
presence of GFP/CD19+ target cells and NOT Her2/GFP/CD19+ target cells 
(representative of at least 3 independent experiments). 
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Figure 2.6. synNotch receptors can integrate OR-gate functionality to program T 
cells with antigen recognition circuits to overcome antigen heterogeneity/escape 
 
(A) Design of a 3-input circuit utilizing a dual synNotch functioning as an OR gate to 
regulate CAR expression: the a-Her2/GFP dual synNotch induces expression of the a-
CD19 41BBz CAR. 
 
(B) Diagram of 2-receptor circuit engineered in primary human CD8 T cells to generate 
an (OR)-AND-gate controlling T cell activation. These T cells are engineered to 
constitutively express a dual-antigen synNotch receptor with two antigen binding 
domains: the N-terminal a-GFP nanobody and a-Her2 scFv connected by a (G4S)3 
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linker (long linker). These T cells must first bind Her2 OR GFP via the dual synNotch to 
induce the a-CD19 41BBz CAR, and should only activate and kill target cells if they 
sense (Her2 OR GFP) AND CD19. 
 
(C) Primary human CD8 T cells were engineered with the a-GFP synNotch, a-Her2 
synNotch, or the a-Her2/GFP dual synNotch controlling the expression of a BFP 
reporter. These T cells were co-cultured at 1:1 E:T for 24 hours with K562 target cells 
expressing Her2, GFP, or neither antigen. Histograms of BFP levels measured via flow 
cytometry show that the dual synNotch specifically responds to either Her2 OR GFP 
positive target cells, while the two single antigen synNotch receptors only respond to 
one of the target cells (representative of at least 3 independent experiments). 
 
(D) Quantification of replicate target cell killing data gathered via flow cytometry after 1:1 
E:T co-cultures of varied times between engineered CD8 T cells shown in (B) and K562 
target cells expressing different combinations of CD19, GFP, and Her2. The T cells 
spare target cells expressing only CD19 but are able to kill CD19 positive target cells 
that also co-express Her2 OR GFP (n=3, error bars are SD). 
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Figure 2.7. Periodic table of multi-antigen CAR T recognition circuits 
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We demonstrated that synNotch T cells can be engineered with an assortment of 
diverse combinatorial antigen recognition circuits. These synNotch T cells can integrate 
information from up to 3 receptors targeting different antigen inputs to generate highly 
cancer-specific target cell killing. Given the modularity of the synNotch system, it may 
now be possible to program therapeutic T cells capable of recognizing any possible 
combinatorial antigen signature identified as cancer-specific. Targeting proof-of-concept 
antigen combinations, we have shown that synNotch T cells can perform a wide range 
of antigen recognition programs based on Boolean logic-gates. As bioinformatic 
analysis of antigen expression in cancer versus healthy cells reveals tumor-specific 
combinations, synNotch T cells can be engineered to meet the targeting needs of 
particular cancers or even individual patients. The demonstrated computational power 
of synNotch T cells means the main limitation of these circuits moving forward may be 
the availability of precise antigen-specific binding domains (e.x. scFv) to use in 
receptors.  
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Figure 2.8. synNotch-driven TCR expression in human primary T cells for AND 
gate control over therapeutic T cell activation 
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(A)  Two-dimensional dot plots of a TCR-deficient Jurkat T cell line before (left plot) and 
after (right plot) transduction with a multicistronic vector with the SFFV promoter 
constitutively expressing mCherry and both TCR chains, each separated by unique 2A 
sequences.  Jurkat T cells were stained with a FITC-conjugated antibody targeting the 
TCRb constant domain.  mCherry and TCR expression were found to be tightly related, 
and in future experiments fluorescent protein_2A reporter systems were used to track 
synNotch-induced TCR expression in primary human T cells that could not simply be 
stained with anti-TCR antibodies.  
 
(B)  Versatility of dual-antigen synNotchàTCR AND gate circuits.  We engineered 
similar circuits with alternative TCRs.  We used a synNotch that targets surface 
expressed GFP (a model synNotch antigen) to drive expression of two other clinically 
important TCRs: a-MART1 TCR (internal antigen; 26-35 peptide presented by HLA-A2) 
or a-NY-ESO1 TCR (internal antigen;157-165 peptide presented by HLA-A2).  Jurkat T 
cells were engineered to express an a-GFP Gal4-VP64 synNotch (external) controlling 
the expression of the a-NY-ESO1 TCR (internal, pMHC) or the a-MART1 TCR (internal, 
pMHC), in separate engineered cell lines.  Engineered synNotch/TCR Jurkat T cells 
were co-cultured for 18 hours at 1:1 E:T with T2 target cells presenting MART1 only, 
GFP and MART1, NY-ESO1 only, or GFP and NY-ESO1.  Histograms of CD69 
activation marker expression level show that both synNotch/TCR Jurkat T cell lines 
specifically activate in response to their corresponding dual-antigen positive T2 target 
cells (representative of at least 3 independent experiments). 
 
(C) Design of a dual-antigen AND gate circuit controlling primary human CD4 T cell 
activation that recognizes an external-internal antigen pair: the a-GFP Gal4-VP64 
synNotch (external) induces expression of the a-NY-ESO1 TCR (internal, pMHC). 
 
(D) Engineered CD4 T cells shown in (C) were co-cultured for 18 hours at 1:1 E:T with 
T2 target cells presenting GFP only, NY-ESO1 only, or both GFP and NY-ESO1. 
Histograms of CD69 activation marker expression level show that the engineered 
synNotch/TCR CD4 T cells specifically activate in response GFP/NY-ESO1+ dual-
antigen positive T2 target cells (representative of at least 3 independent experiments). 
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Figure 2.9. inNotch receptors recognize internal antigens in form of pMHC and 
can be used to control CAR/TCR expression in AND gate T cells 
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(A) Primary human CD4 T cells were engineered to express an internal antigen-sensing 
synNotch (“inNotch”) targeting the cytosolic/secreted protein AFP-derived pMHC and 
utilizing Gal4-VP64 to control expression of a corresponding BFP reporter response 
element.  
 
(B) Engineered CD4 T cells shown in (A) were co-cultured at 1:1 E:T for 24 hours with 
T2 target cells pulsed with a titration of AFP158-166 peptide or off-target WT1 peptide. 
Histograms of BFP levels measured via flow cytometry showed selective reporter 
induction in the presence of AFP, with increasing induction levels in response to 
increasing AFP peptide concentrations.  
 
(C) Design of a dual-antigen AND gate circuit controlling Jurkat T cell activation that 
recognizes an internal-external antigen pair: the a-WT1 Gal4-VP64 inNotch (internal, 
pMHC) induces expression of the a-Her2 41BBz CAR (external). 
 
(D) Engineered Jurkat T cells shown in (C) were co-cultured for 18 hours at 1:1 E:T with 
T2 target cells presenting WT1 only, Her2 only, or both WT1 and Her2. Histograms of 
CD69 activation marker expression level show that the engineered inNotch/CAR Jurkat 
T cells specifically activate in response WT1/Her2+ dual antigen positive T2 target cells 
(representative of at least 3 independent experiments). 
 
(E) Design of a dual antigen AND gate circuit controlling CD8 T cell activation that 
recognizes an internal-internal antigen pair: the a-WT1 Gal4-VP64 inNotch (internal, 
pMHC) induces expression of the a-NY-ESO1 TCR (internal, pMHC). 
 
(F) Forward scatter and side scatter flow cytometry plots of 24 hour 1:1 E:T co-cultures 
between engineered CD8 T cells shown in (E) and T2 target cells presenting WT1 only, 
NY-ESO1 only, or both WT1 and NY-ESO1. T2 target cells fall within the indicated gate. 
The inNotch/TCR AND gate T cells specifically killed the dual-positive WT1/NY-ESO1+ 
T2 cells, as demonstrated by the selective reduction of cells in the T2 gate 
(representative of at least 3 independent experiments). 
 
(G) Quantification of replicate target cell killing data shown in panel (F) (n=3, error bars 
are SD). 
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Figure 2.10. Multiple orthogonal synNotch receptors can be used with a split CAR 
in the same T cell to build 3-input AND gate antigen-sensing circuits 
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(A) Diagram depicting CD4 T cells engineered to test orthogonality of multiple synNotch 
receptors in the same primary human T cell. The T cells were engineered to express (1) 
an a-GFP synNotch receptor with a LexA-VP64 transcription factor controlling mCherry 
reporter expression and (2) an a-Her2 synNotch receptor with a Gal4-VP64 
transcription factor controlling BFP reporter expression.  
 
(B) Engineered T cells shown in (A) were co-cultured at 1:1 E:T for 24 hours with K562 
target cells expressing GFP, Her2, neither, or both antigens.  Bar graphs showing the 
integrated fluorescence signal for both mCherry and BFP reporter outputs demonstrate 
that the LexA- and Gal4-based synNotch receptors function orthogonally in primary 
human T cells (n=2, error bars are range). 
 
(C) Two-dimensional dot plots are shown for data quantified in (B) (representative of at 
least 3 independent experiments). 
 
(D) Flow cytometry plots showing the expression levels of GFP, Her2, and CD19 on 
K562 lines utilized for experiments with 3-input antigen-sensing T cells.  
 
(E) Design of a 2-input AND gate circuit controlling CD8 T cell activation that utilizes a 
synNotch receptor and a split CAR system.  
 
(F) Diagram depicting 2-input synNotch/split-CAR AND gate circuit controlling CD8 T 
cell activation. Primary human T cells were engineered to express an a-Her2 Gal4-
VP64 synNotch controlling expression and secretion of an a-CD19 PNE-tagged adapter 
molecule (CARout) that can interact with a constitutively expressed a-PNE 41BBz CAR 
(CARin). These T cells should only activate and kill target cells if they sense both Her2 
and CD19. 
 
(G) Quantification of replicate target cell killing data gathered via flow cytometry after 
1:1 E:T co-cultures for 24 hours between engineered CD8 T cells shown in (F) and 
K562 target cells expressing different combinations of Her2, CD19, or both antigens. 
The T cells spare target cells expressing only CD19 but are able to kill CD19 positive 
target cells that also co-express Her2 (n=2, error bars are range). 
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Figure 2.11. offNotch-regulated T cell apoptosis can be used to integrate negative 
regulation into 3-input antigen-sensing circuits 
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(A) Diagram depicting the offNotch NOT module engineered in primary human CD8 T 
cells: an a-Her2 Gal4-VP64 synNotch induces expression of pro-apoptosis protein tBID.  
 
(B) Quantification of replicate T cell survival data gathered via flow cytometry after 1:1 
E:T co-cultures for 48 hours between engineered CD8 T cells shown in (A) and K562 
target cells with or without Her2 expression. While survival of untransduced control T 
cells did not depend on the antigen expression of co-cultured K562 cells, offNotch T 
cells showed reduced survival after co-culture with Her2 positive K562 target cells (n=3, 
error bars are SD). 
 
(C) Forward scatter and side scatter flow cytometry plots corresponding to 96 hour time 
point in data shown in Figure 5C. K562 target cells fall within the indicated gate. The 
3AND-NOT circuit T cells specifically killed the GFP/CD19+ K562 cells and spared 
Her2/GFP/CD19+ K562 cells, as demonstrated by the selective reduction of cells in the 
K562 gate (representative of at least 3 independent experiments). 
 
(D) Primary human CD4 T cells were engineered with the circuit shown in Figure 5B. 
These engineered CD4 T cells were tested in the same timecourse experiments as the 
data is shown for CD8s in Figure 5C. Very similar to the CD8s, these CD4 T cells 
specifically killed the GFP/CD19+ K562 cells and spared Her2/GFP/CD19+ K562 cells 
(n=3, error bars are SD).  
 
(E) Quantification of CD4 T cell numbers via flow cytometry after 96 hours in the co-
culture experiment described in (D). Very similar to the CD8s, the CD4 T cell counts 
show selective expansion when T cells were co-cultured with GFP/CD19+ target cells 
and NOT Her2/GFP/CD19+ target cells (n=3, error bars are SD). 
 
	 112	
 
Figure 2.12. dual-antigen synNotch receptors function as OR gates with tunable 
performance in combinatorial antigen sensing T cells 
 
(A) Design of a 3-input circuit utilizing a dual synNotch functioning as an OR gate to 
regulate CAR expression: an a-Her2/GFP dual synNotch with a variable linker induces 
expression of the a-CD19 41BBz CAR. 
 
(B) Quantification of replicate target cell killing data gathered via flow cytometry after 1:1 
E:T co-cultures for 24 hours between engineered CD8 T cells shown in (B) and K562 
target cells expressing different combinations of CD19, GFP, and Her2. The T cells 
spare target cells expressing only CD19 but are able to kill CD19 positive target cells 
that also co-express Her2 OR GFP, and the level of killing depends on the identity of 
the linker used in the dual synNotch (n=3, error bars are SD). 
 
(C) Forward scatter and side scatter flow cytometry plots corresponding to target cell 
killing data shown in (B) (representative of at least 3 independent experiments). 
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Chapter 3 – DNA-scaffolded biomaterials enable modular and 
tunable presentation of proteins to control immune cell 
therapies 
 
ABSTRACT 
 Advanced biomaterials provide versatile ways to spatially and temporally control 
immune cell activity, potentially enhancing their therapeutic potency and safety. Precise 
cell modulation demands multi-modal display of functional proteins with controlled 
densities on biomaterials. Here, we develop an artificial immune cell engager (AICE) 
platform - biodegradable particles onto which multiple proteins are densely loaded with 
ratiometric control via short nucleic acid tethers. We demonstrate that AICE with varying 
ratios of anti-CD3 and anti-CD28 antibodies modulate the ex vivo expansion of human 
primary T cells. We also show that AICE presenting a critical density of antigens can 
control the activity of engineered T cells in vivo. AICE injected intratumorally can 
provide a local priming signal for systemically administered AND-gate chimeric antigen 
receptor T cells, driving local tumor clearance while sparing uninjected tumors that 
model potentially cross-reactive healthy tissues. This modularly functionalized 
biomaterial provides a flexible platform to achieve control over cell-based 
immunotherapies both during manufacturing and in the body throughout treatment. 
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INTRODUCTION 
Functionalized biomaterials can work together with natural or engineered 
immune cells for cancer immunotherapy. Adoptive cell therapy (ACT) using chimeric 
antigen receptor (CAR) engineered T cells has shown success and clinical approval for 
the treatment of B cell cancers (June & Sadelain, 2018). However, for CAR T cells to 
fulfill their promising potential, particularly for targeting solid tumors (Chen & Mellman, 
2013; Gajewsky et al., 2013), important challenges must be overcome to improve both 
efficacy (Adachi et al., 2018; Wallace et al., 2008) and safety (Brudno & Kochenderfer, 
2016; Riches et al., 2013; Gust et al., 2017; Maus et al., 2013). For engineered anti-
tumor T cells to achieve durable tumor remissions, a demanding manufacturing process 
is required to ensure the quantity and quality of the cell product for therapeutic use 
(Riley et al., 2019; Cheung et al., 2018; Tumeh et al., 2010; Brenner et al., 2018). To 
increase the tumor targeting specificity and avoid “on-target, off-tumor” toxicity in 
bystander healthy tissues (Roybal et al., 2016), CAR-T cells have been engineered with 
combinatorial antigen AND-gate activation control that requires sensing two antigens on 
a target cell to initiate killing. The clinical application of this strategy, however, requires 
systematic identification of tumor specific antigen combinations and would also benefit 
from better control of cell activity (Brenner et al., 2018; Lim & June, 2017). 
Biomaterials functionalized with modulatory biomolecules at pre-specified 
densities have been shown to communicate with and control therapeutic immune cells 
both ex vivo and in vivo. For example, synthetic materials have been functionalized with 
agonistic antibodies for CD3 and CD28 to drive ex vivo T cell expansion (Cheung et al., 
2018; Tumeh et al., 2010). Biodegradable materials with optimized material 
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structure/composition and controlled surface moiety loading can provide unique 
opportunities to improve the ease of manufacturing and the quantity and quality of T 
cells produced. There is also a growing interest in the use of biomaterials for local 
modulation of engineered T cell activity in vivo during the course of treatment (Riley et 
al., 2019). 
However, the use of biomaterials to precisely modulate immune cells still faces 
key challenges. There is a need for robust chemical conjugation strategies to surface-
functionalize biodegradable materials with multiple signals (e.g. proteins/antibodies) at 
high densities and precisely controlled ratios (Shi et al., 2017; Sapsford et al., 2013; 
Iyisan & Landfester, 2019; Schmid et al., 2017). PEG (polyethylene glycol) is commonly 
used as a linker or scaffold for the surface conjugation of biomolecules31, but this 
method is limited by the inefficient presentation of functional groups for attaching 
biomolecules due to PEG’s flexibility (Sapsford et al., 2013). Synthetic short 
oligonucleotides - natural polymers with controllable sequence and structure - have 
been used as surface scaffolds on metallic particles for siRNA delivery (Huang et al., 
2017; Hu & Niemeyer, 2019; Wang et al., 2019; Peterson & Heemstra, 2015), but have 
yet to be fully utilized for modular payload assembly on biodegradable materials. 
In this work, we developed short synthetic DNA scaffolds for the efficient and 
versatile functionalization of proteins or antibodies on the surface of PLGA (or other 
biodegradable polymer) particles (Fig. 3.1A). A series of optimization studies were 
carried out to achieve maximum loading density, ratiometric control of protein loading, 
adaptability to different particle size/composition, and feasibility for in vivo use. Micron-
sized artificial immune cell engagers (AICE) were made from biocompatible poly(lactic-
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co-glycolic acid) (PLGA) polymer (Allahyari & Mohit, 2016) (Fig. 3.1A). We 
demonstrated that: i) we can load a range of immune modulators (e.g. anti-CD3, anti-
CD28, and IL-2) on AICE at controlled ratios and densities; ii) the ratiometric control of 
costimulatory ligands is essential for optimal ex vivo T cell activation and expansion with 
higher yield and less exhaustion; iii) we can locally administer antigen-presenting AICE 
to control AND-gate CAR-T cell activation and tumor clearance in vivo (Fig. 3.1A). This 
modular materials-based strategy can provide versatile and precise synthetic control of 
natural or engineered immune cells for cancer immunotherapy (Riley et al., 2019; Jiang 
et al., 2017; Lim & June, 2017).  
 
RESULTS 
 
Fabrication of surface DNA scaffolded polymeric particles 
Synthetic short DNA strands were immobilized on the surface of polymeric 
particles to create an adaptable scaffold for loading bioactive molecules. The emulsion 
protocol of particle synthesis (Allahyari & Mohit, 2016) was modified to add conjugated 
polymer-DNA amphiphilic molecules during the fabrication process such that the 
hydrophilic DNA segment distributes around the hydrophobic core upon sonication (Fig. 
3.1B). Polymer-DNA molecules were first synthesized through a conjugation of thiol-
modified DNA to Maleimide (Mal)-modified polymer. We optimized the polymer, DNA 
length, solvent, and reaction conditions to generate optimal polymer-DNA molecules to 
form stable PLGA (50:50, MW 38-54k, Sigma) particles with dense DNA scaffolds (Fig. 
3.6A-D). PLGA10k-PEG5k-Mal was identified as an important polymer-DNA component 
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to ultimately form microparticles of the desired size (1-2 µm in diameter). Increasing the 
excess of DNA input into the polymer conjugation reaction resulted in an increase in 
polymer coupling efficiency (Fig. 3.1C).  
The direct incorporation of polymer-DNA reaction mixtures with different 
DNA:polymer ratios into the particle fabrication protocol yielded a significant increase of 
surface payload-attachable DNA scaffold density, as determined by a fluorescence-
based hybridization analysis (Fig. 3.1D). Strikingly, the highest average surface loading 
density on particles (~5 million DNA duplexes per particle, Fig. 3.6E-G) was roughly 
analogous to the theoretical limit (at ~4 million by footprint calculation, based on ~2 nm 
diameter of DNA duplex) of a spherical particle with a 2 µm diameter. In particular, this 
hybridization-guided loading was about 27-fold more efficient than that from the 
traditional method (Schmid et al., 2017), in which thiol-modified DNA molecules were 
conjugated to surface-exposed Mal groups after particle fabrication using equal input 
amount of PLGA10k-PEG5k-Mal (Fig. 3.1D). The hybridization-guided biomolecule 
assembly protocol was optimized to a 30-minute incubation at 37oC (Fig. 3.6H), and 
functionalized particles can be further lyophilized for storage and transportation (Fig. 
3.6I).  
To accommodate diverse applications from intracellular payload delivery to 
extracellular signal transduction, DNA-scaffolded particles can be synthesized at 
various sizes and also loaded with biomolecules in their core. Particle size can be 
controlled by tuning key emulsion parameters (Fig. 3.1E and Fig. 3.6J). We observed a 
concave shape on one side for some larger particles (~2 µm in diameter) but not for 
smaller particles (~500 nm) (Fig. 3.1F) possibly due to the high surface hydrophilicity 
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with DNA scaffolds leading to higher surface to volume ratio. Additionally, we showed 
that the core of these DNA-scaffolded microparticles could also be loaded with 
biomolecules including oligonucleotides and peptides through a double-emulsion 
protocol (Fig. 3.1G and Fig. 3.6K). This strategy of fabricating DNA-scaffolded particles 
was also successfully replicated using other polymers such as polylactic acid (PLA) 
(Fig. 3.1H, Fig. 3.6L and Fig. 3.6M).  
 
Multi-functionalization of DNA-scaffolded particles 
Biomolecules can be loaded on the surface of DNA-scaffolded particles using 
one of two strategies: a) linking functional groups of the scaffolds to biomolecules 
through the surface step-by-step conjugation via a bifunctional linker; and b) through the 
direct hybridization of complementary DNA-biomolecule conjugates to the scaffold (Fig. 
3.2A). In the case of a fluorescently labeled human IgG, the surface conjugation 
strategy resulted in saturated protein loading even with increased densities of available 
DNA linkers on surface (Fig 3.2B, Fig 3.1D and Fig. 3.7A). In contrast, the 
hybridization-guided assembly strategy showed a dramatically higher level of IgG 
loading for particles with denser DNA linkers, and the increase in IgG loading 
corresponded to the scaffold density (Fig. 3.2B). The highest level of IgG loading 
achieved (at ~0.6 million per particle) was again comparable to the theoretical footprint 
limit of a spherical particle at 2 µm in diameter (~0.64 million per particle, based on ~5 
nm diameter of IgG) (Fig. 3.2B). For generating DNA-antibody conjugates with the 
minimum damage to the antibody activity, different chemistries (Fig. 3.7B and Fig. 
3.7C) were attempted and the “TCEP” strategy (Zamecnik et al., 2017) was identified as 
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optimal, whereby the antibody hinge region was selectively reduced to expose the thiol 
group for 3’NH2-modified complimentary DNA to attach through a MAL-dPEG4-NHS 
linker (Quanta Biodesign). For example, anti-PD-L1 antibody conjugated with DNA 
through this strategy showed intact binding activity (Fig. 3.7C), and its loading on PLGA 
microparticles resulted in high binding specificity for PD-L1 positive cells (Fig. 3.2C). 
For DNA tethering of proteins other than antibodies, other options are available to yield 
products with intact activity (Fig. 3.7D and Fig. 3.7E). 
Another advantageous feature of using DNA as a surface scaffold is that the 
uniqueness of nucleotide sequences enables the independent control of loading 
multiple cargos on the same material surface (Fig 3.2D). Polymer-DNA conjugates with 
three distinct DNA sequences (namely R, G, and B strand) that do not anneal with each 
other (Fig. 3.7F) were synthesized and incorporated into particle emulsion with reaction 
mixtures at different ratios (3:1:1, 1:1:1 and 1:1:3). After surface hybridization with a 
mixture of their respective dye-labeled complementary strands (Fig. 3.2D), we found 
that the ratios of hybridized DNA scaffolds of different sequences on PLGA 
microparticles were consistent with the polymer-DNA conjugate input, evidenced by 
both confocal fluorescence imaging (Fig. 3.2E) and a fluorescence-based quantification 
assay (Fig. 3.2F). The ratiometric control of dye-labeled DNA strand loading was 
equally efficient for PLA microparticles (Fig. 3.7G and Fig. 3.7H). Based on this, we co-
loaded three different proteins (GFP and two antibodies), each individually attached with 
one of the three complementary DNA strands, onto PLGA microparticles with varying 
ratios of the DNA surface scaffold sequences above. Similar distribution of each protein 
cargo compared with the scaffold population was observed (Fig. 3.2G), demonstrating 
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the robust ratiometric control of surface protein loading using this particle synthesis 
strategy. 
To enable in vivo use, we explored the stability of the DNA scaffolds on the 
surface of PLGA microparticles in the presence of a large excess of DNase (Fig. 3.2H). 
We observed an almost complete (~87%) degradation of DNA scaffolds after DNase 
treatment; however, this dropped down to ~20% with IgG molecules conjugated to the 
scaffolds through the surface step-by-step conjugation (~1/4 of the highest IgG loading 
through hybridization-guided assembly) (Fig. 3.2b and Fig. 3.2I). This suggests that the 
surface-loaded proteins are able to protect the DNA scaffolds. In human serum, we did 
not observe as significant DNA degradation for the naked particles due to the lower 
DNase concentration in serum than used in Fig.2i; however, the degree of DNA 
degradation similarly decreased as surface payload proteins were attached (Fig. 3.2J). 
Macrophage uptake is a major obstacle (Blanco et al., 2015) for particle-based 
drug delivery in vivo, therefore we incorporated a CD47-mimic “self”-peptide (Rodriquez 
et al., 2013) on PLGA microparticles (Fig. 3.2K). Fluorescein-labeled PLGA 
microparticles with and without surface-loaded “self”-peptide were co-incubated with a 
mouse macrophage line J774A.1 in vitro. The particle uptake assay showed that the 
“self”-peptide decoration significantly reduced the uptake of particles by macrophages 
(Fig. 3.2K, Fig. 3.7I and Fig. 3.7J). This “self”-peptide functionalization provides a 
possible strategy to reduce the clearance of particles in vivo. 
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Design of particles with ratiometrically controlled moieties for ex vivo human T 
cell activation 
Given the ability to synthesize particles with ratiometric control of multiple surface 
cargos, we loaded anti-CD3 and anti-CD28 antibodies on AICE (PLGA microparticles) 
at varying ratios from 1:5 to 5:1. Anti-CD3/CD28 AICE were used to activate human 
primary T cells ex vivo and compared to commercial anti-CD3/CD28 Dynabeads at the 
same particle to cell ratio for the ability to expand T cells (Fig. 3.3A). Functionalized 
AICE activated T cells (Fig. 3.3B) and yielded massive cell expansion across three 
human T cell donors (Fig. 3.3C). Although there were large donor-to-donor differences 
(also observed for Dynabeads), we observed a linear increase of cell yield from AICE-
[1:5, anti-CD3:anti-CD28] to AICE-[3:1] for both CD4+ and CD8+ cells at day 14 (Fig. 
3.3C and Fig. 3.8A). The phenotype of expanded T cells at day 14 was then explored 
by measuring expression of CD45RA and CCR7 surface markers (Fig. 3.3D). 
Interestingly, the population distribution of the 4 differentiation states (naïve, central 
memory [CM], effector memory [EM] and effector memory RA [EMRA]), displayed a 
pattern (Fig. 3.3E and Fig. 3.8B) corresponding to the cell expansion trend among 
AICE with different anti-CD3 to anti-CD28 ratios (Fig. 3.3C). AICE-[3:1] among tested 
conditions yielded higher average expansion of CD8+ T cells from the three donors 
(Fig. 3.3F) and equivalent expansion of CD4+ T cells, compared to Dynabeads 
activation (Fig. 3.8D). Through staining for T cell exhaustion markers LAG-3, PD-1 and 
TIM-3, we found that the population of exhausted cells at the optimal condition AICE-
[3:1] was less abundant than those activated by Dynabeads among the three donors 
(Fig. 3.3G). Taken together, the data demonstrates that the surface ratio control of 
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functional moieties on synthetic materials is important for the quantity and phenotype of 
cells yielded from ex vivo T cell expansion. 
As an alternative to the standard protocol of supplementing free IL-2 in the media 
for ex vivo T cell culture (Cheung et al., 2018), we loaded IL-2 on AICE through the 
surface presentation via its antibody clone #5355 (Fig. 3.8E). This particular anti-IL-2 
antibody was engineered to facilitate the binding of IL-2 to its b and g receptor on T cells 
thus promoting the proliferation of non-Treg T cells (Arenas-Ramirez et al., 2016) (Fig. 
3.3H and Fig. 3.8F). Using the optimal condition of AICE[3:1] (anti-CD3:anti-CD28) 
determined above, we compared primary T cell expansion by supplementing equal 
amount of free IL-2 versus surface bound IL-2 (Fig. 3.8E). Surface IL-2 loading 
enhanced CD4+ and CD8+ T cell expansion, and particularly improved expansion of 
CD4+ primary T cells after day 8 (Fig. 3.3I,J and Fig. 3.8A,G). Although with higher 
level of cell yield, the populations of LAG-3 and PD-1 positive CD4+ T cells still 
decreased in the two tested donors (Fig. 3.8H), demonstrating the advantages of AICE-
surface presentation of IL-2 for ex vivo expansion. 
 
Design of particles to prime activation of AND-gate CAR-T cells  
We also explored the use of AICE coated with an orthogonal antigen (GFP) to 
prime AND-gate CAR-T cell tumor recognition circuits, with the goal of preventing ON-
target OFF-tumor toxicity by restricting cell killing to tumors locally-injected with AICE 
microparticles (Fig 3.4A). These AND-gate T cells utilize a modular synthetic Notch 
(synNotch) receptor with an extracellular domain to recognize a target antigen, and an 
intracellular transcriptional activator (TF) domain to control expression of a CAR 
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targeting a second antigen (Roybal et al., 2016). Killing is only induced when both 
antigens are presented to T cells, with one activating the synNotch receptor to release 
the TF domain for CAR expression and the other activating CAR-mediated cytotoxicity. 
Herein, human primary T cells were transduced with a gene encoding a constitutively-
expressed synNotch receptor with an extracellular anti-GFP nanobody and an 
intracellular Gal4DBD-VP64 synthetic transcription factor (TF) domain, together with a 
TF-inducible CAR gene targeting HER2 (human epithelial growth factor receptor 2) (Fig. 
3.4A). In this system, T cells should only express the anti-HER2 CAR and kill HER2+ 
target cells after priming via the anti-GFP synNotch binding AICE-presented GFP.  
Human primary CD8+ T cells engineered with the above circuit were co-cultured 
for 24 hours with single antigen target cells (human melanoma cell line A375 with HER2 
overexpressed) in the presence or absence of GFP+ AICE microparticles. 
SynNotch/CAR T cells showed selective elevation of the early activation marker CD69 
in the presence of both HER2+ A375 cells and GFP+ AICE, and the activation was 
similar to T cells exposed to dual antigen target cells (human leukemia cell line K562 
with GFP and HER2 co-expressed) (Fig. 3.4B). For both CD4+ and CD8+ engineered 
primary T cells, we observed selective secretion of cytokines (IL-2 and IFN-g, 
respectively) after 48 hours of co-culture with both HER2+ A375 cells and GFP+ AICE 
(Fig. 3.4C). Increasing AICE GFP density led to elevated levels of cytokine secretion 
(Fig. 3.4C and Fig. 3.9A). Noticeably, T cells secreted significantly more cytokines with 
AICE presenting synNotch-priming GFP than with target cells presenting both synNotch 
and CAR antigens (A375 with GFP and HER2 co-expressed) (Fig. 3.9B).  
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Human primary CD8+ T cells containing the same circuit as above also showed 
AND-gate killing behavior, selectively killing HER2+ A375 cells in the presence of GFP+ 
AICE microparticles. Co-incubation of GFP+ AICE and CD8+ human primary T cells led 
to some killing of co-cultured HER2+ A375 cells (with 1:1 ratio) at 24 hours (Fig. 3.4D 
and Fig. 3.4E), and the killing became more apparent after 48 hours with higher 
densities of priming signals on AICE (Fig. 3.4F and Fig. 3.9C-F). In contrast, initial 
attempts using particles synthesized by traditional conjugation chemistry and with far 
lower GFP density failed to activate AND-gate CAR-T cells, likely due to the inadequate 
ligand density for robust synNotch activation. As a demonstration of adaptability for 
translational use, a synthetic short peptide (PNE peptide) computationally predicted to 
be non-immunogenic (Rodgers et al., 2016) was engineered on AICE and co-incubated 
with its corresponding a-PNE synNotch/a-HER2 CAR CD8+ T cells and HER2+ target 
cells, and killing was significantly enhanced by PNE+ AICE addition (Fig. 3.9G). The co-
incubation of target cells with synNotch CAR-T cells in the absence of AICE also 
showed moderate cytotoxicity (Fig. 3.4F and Fig. 3.9C-G), which is likely due to the 
leakiness of CAR expression also observed from previous reports and can be improved 
through optimization of synNotch receptors.  
 
Local tumor eradication in mouse model by the combinatorial treatment of 
priming particles and AND-gate T cells 
To determine the feasibility of using local particle injections to send spatially-
defined signals to therapeutic cells in vivo, we first monitored the distribution of 
intratumorally-injected AICE microparticles. We labeled surface DNA and polymer core 
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with two distinct infrared dyes (Quasar705 and IR800CW respectively, Fig. 3.10A) on 
microparticles composed of PLGA (~1.5 µm in averaged diameter) and PLA polymer 
(~1.9 µm in averaged diameter). AICE particle retention and half-life were then explored 
in vivo by injection into subcutaneous K562 xenograft tumor in NSG mice followed by 
the IVIS near-infrared fluorescence imaging at different time points. AICE were retained 
locally within the tumor for over a week (Fig. 3.5A and Fig. 3.10B), and the 
fluorescence quantification showed an approximate half-life of 4-5 days for the surface 
coating of both types of particles (Fig. 3.5B and Fig. 3.10C-E). These results 
demonstrate that AICE injection can be used to send localized, sustained signals to 
therapeutic cells during the course of treatment. 
We hypothesized that AICE made of GFP decorated PLGA microparticles could 
be injected intratumorally as a local activator for systemically administered anti-GFP 
synNotch/anti-HER2 CAR T cells (Fig. 3.5C). NSG mice were implanted 
subcutaneously with the same HER2-overexpressed K562 xenograft tumors in bilateral 
flanks as a model for a tumor and healthy tissue both expressing the CAR antigen. After 
a week, mice were administered synNotch CAR-T cells once intravenously in 
combination with AICE intratumorally injected for 4 doses (Fig. 3.5C). The size of AICE-
injected ipsilateral tumors decreased over time, in contrast to the contralateral tumors 
within the same mice without AICE injection and tumors in mice injected with AICE plus 
untransduced primary T cells (Fig. 3.5D-G). We also performed fluorescence 
microscopy on fixed tumor samples of mice sacrificed at an early timepoint and 
observed selective T cell infiltration in the AICE-injected tumor (Fig. 3.5H and 3.10F). 
These results demonstrate that AICE can provide a spatially controlled signal in vivo for 
	 126	
the local activation of synNotch CAR-T cells and induction of precision tumor clearance 
with limited risk of cross-reaction against healthy tissues.  
 
DISCUSSION 
In this work, we demonstrate a unique platform using synthetic short DNA 
oligonucleotides as surface scaffolds on biodegradable materials for the precise and 
controlled loading of multiple biomolecules at specific ratio and density. These 
advanced biomaterials possess the ability to regulate immune cells in the context of ex 
vivo and in vivo activation of both natural and engineered T cells. Through this highly 
modular platform, biocompatible materials can be employed as substrates for a wide 
spectrum of modulatory biomolecules, including cytokines (Tang et al., 2018), antigens 
(Singha et al., 2017), checkpoint inhibitors (Rafiq et al., 2018), agonistic or antagonistic 
antibodies (Huang et al., 2015), adjuvants (Yu et al., 2018; Smith et al., 2017; Kuai et 
al., 2017), etc., to regulate the local environment and enhance the efficacy of immune 
cells in cancer immunotherapy (Shao et al., 2015; Stephan et al., 2010; Wang et al., 
2017). Synthetic materials with tunable properties can enhance the pharmacokinetics of 
regulatory biomolecules in vivo (Riley et al., 2019; Zamecnik et al., 2017; Wang et al., 
2017), and sometimes provide a necessary surface substrate for biomolecules to 
activate the cognate cell signaling (Singha et al., 2017; Cheung et al., 2018; Roybal et 
al., 2016). Biomaterials fabricated with controlled size, shape, and composition - for 
example, microspheres, nanowires, and porous scaffolds - can also serve as a local 
adjuvant (Shah et al., 2019; Chen et al., 2019; Ye et al., 2017; Stephan et al., 2015) for 
biomolecules or engineered immune cells to exert tumor targeted toxicity without 
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systemic diffusion, thus minimizing the off-target side effects. This can make a particular 
difference for solid tumor treatment, where functionalized biomaterials could be 
administered locally or engrafted post-surgery (Chen et al., 2019; Chen et al., 2013; 
Mariathasan et al., 2018).  
Here we explored using a natural polymer, DNA, as the surface scaffold for 
loading biomolecules onto particles. We demonstrated, through near surface-saturated 
biomolecule loading and precise ratiometric control of moiety loading, that hybridization-
based thermodynamics can overcome limitations of traditional surface conjugation such 
as reduced efficiency of multi-step reactions, steric hindrance, and decay of functional 
groups. The increased loading density of surface biomolecules was found to be 
necessary to make particles capable of presenting antigens to robustly activate 
synNotch receptors in primary human T cells, and may also significantly enhance 
immune cell signaling where ligand clustering is required (Signha et al., 2017; Taylor et 
al., 2017). We also show the versatility of this strategy by fabricating particles of 
different sizes, as well as compositions with different degradation profiles. This method 
can be applied to other formats of biomaterial functionalization (e.g. scaffolds and 
nonspherical particles) where fragile biomolecules need to be presented at a material 
interface. 
    The densely-packed surface DNA scaffolds and the payload attachments 
protected DNA linkers from enzymatic degradation, which shows great promise for in 
vivo use. This organized packing of the particle surface with a protein corona may also 
minimize interactions with serum proteins to prevent macrophage clearance (Oh et al., 
2018). Furthermore, particle uptake by macrophages can be attenuated through the 
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immobilization of a CD47 mimic “self”-peptide (Rodriguez et al., 2013). Safety concerns 
about immunogenicity from the DNA scaffolds can be addressed through optimization of 
sequences and special modifications (Behlke, 2008).  
    The precise ratio of agonistic antibodies (anti-CD3 and anti-CD28) for T cell 
activation on AICE impacts ex vivo T expansion efficiency, as well as T cell 
differentiation and exhaustion phenotypes. The ability to accurately control the ratio of 
multi-cargo particle loading should enable identification of novel, precise combinations 
of modulatory signals that lead to diversified and improved T cell behavior. The use of 
biodegradable materials also omits the need for synthetic material removal prior to cell 
implantation. Cumulatively, these properties suggest that AICE could aid in 
manufacturing for ACT by improving the ease-of-production and fine-tuning the yield 
and phenotype of the therapeutic cell product. 
    We and other groups have developed strategies to engineer T cells with multiple 
receptors to detect combinations of antigens (Brenner et al., 2018; Roybal et al., 2016; 
Lim & June, 2017). All prior combinatorial antigen recognition systems have targeted 
combinations of antigens expressed on tumor cells and/or tumor-related cells. Here, we 
demonstrate a method to engineer T cells to recognize combinations of endogenous 
and orthogonal antigens presented by tumor cells and biocompatible materials, 
respectively. By incorporating material-presented antigen into combinatorial recognition 
circuits, we enable real-time controlled local activation of these circuits that can be 
achieved through dynamic particle dosing in living organisms/patients. Local injection of 
our particles serves to safely control receptor activation and downstream behavior of 
therapeutic cells in vivo.  
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We demonstrated that synNotch-based combinatorial antigen recognition circuits 
can incorporate material-presented antigen sensing, and it is likely that other 
combinatorial antigen recognition systems, for example, chimeric costimulatory 
receptors (CCRs) (Kloss et al., 2013) in AND-gates or inhibitory CARs (iCARs) 
(Fedorov et al., 2013) in NOT-gates, can as well. The use of materials to provide 
antigen input to therapeutic cells enables far enhanced spatiotemporal control of these 
cells.  By controlling pharmacokinetic properties of the particles and the location and 
frequency of injections, it is now possible to dynamically control the local activity of 
therapeutic cells over the course of treatment.  Theoretically, the treatment of any tumor 
that can be reached by an injection device could be made safer by combining local 
particle administration with dosing of engineered combinatorial antigen-sensing T cells 
targeting a non-natural combination of antigens on the particles and tumor cells. 
    We believe that the true promise of the AICE platform will be realized by using 
particles to present multiple signals within the tumor microenvironment. AICE particles 
could kick-start tumor killing by triggering CAR expression by synNotch-CAR T cells. T 
cell activity within the tumor could be further augmented by co-functionalization of AICE 
particles with additional cargos that go beyond a synNotch ligand, for instance, a 
costimulatory ligand and a checkpoint inhibitor tailored to circumvent the specific 
immune evasion mechanisms of a particular tumor type (Chen & Mellman, 2013; 
Mariathasan et al., 2018). In the future, intratumoral injection of AICE particles to initiate 
antigen-specific local immunity by AND-gate CAR T cells could be converted into 
antigen spreading and a systemic immune response by incorporating other cues 
onto/into the particles to stimulate innate immunity (Gajewski et al., 2013).  
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METHODS 
 
Synthesis of Thiol-modified DNA  
3’Thiol-modified DNA were synthesized on 3’thiol-modifier 6 S-S CPG beads 
(Glen Research #10-1936-02) using an Expedite 8909 DNA synthesizer. DNA oligos 
were retrieved from the beads by 70oC incubation for 20 mins in the presence of AMA 
solution (Ammonium hydroxide:Methylamine=1:1,v/v), followed by vacuum evaporation 
(SpeedVac, ThermoFisher #SPD121P-230) for 3 hours to remove AMA. DNA oligos 
were reconstituted in TE buffer (Tris-EDTA, 10mM, pH7.5) and then filtered through 
0.22 µm filter (Millipore #UFC30GV00), and stored at -20 oC. 
 
Synthesis of polymer-DNA amphiphilic molecule  
3’Thiol-modified DNA oligos were deprotected by treating with 100x molar excess 
of Tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP, Sigma #646547) at 37 
oC for 1 hour, and purified by size-exclusion chromatography (Glen Research #61-
5010). Unless otherwise specified, freshly prepared thiol-DNA 17mer at 200 µM were 
reacted with poly(lactide-co-glycolide)-b-poly(ethylene glycol)-maleimide (Mw 
10,000:5000 Da, PLGA10k-PEG5k-Mal, Akina #AI053) at 1:1 ratio in the solvent of 
dimethylformamide (DMF)/H2O (90:10,v/v) with the addition of 0.2% triethanolamine, 
and incubated at room temperature overnight. The next day the solvent was removed 
by vacuum evaporation at 70oC for 3 hours, and the dried mixture was stored at -20oC. 
The product was verified by TBE-Urea gel electrophoresis (15%, ThermoFisher 
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#EC68855) with SYBR gold dye staining (ThermoFisher #S11494), and the conjugation 
efficiency was quantified by gel densitometry analysis. 
 
Fabrication of polymeric particles with DNA scaffolds 
For the fabrication of PLGA particles with varying sizes (Fig. 3.6J), dried 
polymer-DNA reaction mixture (from 100 nmol of each reactant) reconstituted in 200 µL 
solvent (ethyl acetate:H2O=1:1,v/v) was incorporated into the mixture of 0.5 mL ethyl 
acetate (EtOAc) with certain amount of unmodified polymer (Poly-lactic-co-glycolic acid, 
50:50, Mw 38,000-54,000, Sigma #719900), and 0.5 or 1.0 mL aqueous buffer (10mM 
sodium citrate, 600 mM Na+, pH3.0) with or without 1% polyvinyl alcohol (PVA, Sigma 
#81381). The whole mixture was then vortexed and probe-sonicated (Fisher miniRoto 
S56) on ice at 7-8 W for 5 x 5 s with 10 s intervals, and immediately added with 9 mL 
0.2% PVA and stirred in the hood for 3 hours for ethyl acetate to evaporate. Particles 
were filtered through 40 µm cell strainer (Sigma #CLS431750), and washed through the 
centrifugation at 10,000x g for 10 mins followed by the resuspension of pellet in TE 
buffer (10mM Tris-HCl, pH8.0) with 0.01% Tween-20 added. This washing protocol 
stayed the same to later fabrications. After three washes, particles were suspended in 
TE buffer with 1% PVA and lyophilized (VirTis Advantage Plus) for long term storage. 
Particle size profile was characterized by dynamic light scattering (DLS) with a Malvern 
Nano ZS instrument, and SEM imaging using a Zeiss Ultra-55 scanning electron 
microscope. Particle concentration was normalized by the optical density at 550 nm 
(OD550) measured from a UV-Vis spectrometer (Molecular Devices SpectraMax M5).  
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PLA microparticles fabrication used the same protocol but adjusted emulsion 
mixture: 0.5 mL dichloromethane (DCM) with 100 mg/mL polylactic acid (Mw 60,000, 
Sigma #38534), 0.5 mL aqueous buffer (10 mM sodium citrate, 600 mM Na+, pH3.0) 
and the polymer-DNA reaction (from 200 nmol of each reactant) reconstituted in 200 µL 
solvent (ethyl acetate:H2O=1:1,v/v). To encapsulate biomolecules in the core of DNA-
scaffolded particles, another emulsion step was added prior to the above emulsion: 
biomolecules including 0.25 mg FITC-labeled peptide with 21 amino acids (LifeTein) 
and 50 nmol 5’Cy3-labeled DNA-21mer (Bioresearch Technologies) dissolved in 50 µL 
PBS (phosphate buffered saline, pH7.0) was mixed into 0.5 mL ethyl acetate with 
dissolved PLGA (Sigma #719900), and probe-sonicated at 7-8 W for 5 x 5 s with 10 s 
intervals on ice. Immediately after this, amphiphilic polymer-DNA and aqueous buffer 
was added following the same protocol described above. 
 
Attachment of complementary DNA to proteins and their purification  
Antibodies were attached to complementary DNA strands through the “TCEP” 
strategy. Various modified complementary DNA strands were all from Biosearch 
Technologies. Antibodies were first exchanged in reducing buffer (PBS with 10 mM 
EDTA) by size exclusion chromatography (Zeba Spin Desalting Column, ThermoFisher 
#89882), and the disulfide bond at the hinge region was selectively reduced by adding 
TCEP with 3 molar or 4.5 molar excess and incubating at 37°C for 1 hour. Excess 
TCEP was removed through size exclusion chromatography. 3’-NH2 modified 
complementary DNA was conjugated with a MAL-dPEG4-NHS linker (Quanta Biodesign 
#10214) with 30-fold molar excess in HEPES buffer (pH7.0) at 37°C for 1 hour, followed 
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by the removal of the unconjugated linker through 70% ethanol precipitation and size 
exclusion chromatography. Reduced antibody and modified DNA were combined with 
the molar ratio of 1:10, and incubated at 37°C for 1 hour and 4°C overnight. The next 
day, DNA-protein conjugates were purified using protein G affinity chromatography 
(Genscript #L00209) to remove unconjugated DNA.  
Anti-PD-L1 (Bio X cell #BE0285) antibody was conjugated with 3’NH2-
5’Quasar570 modified DNA 22mer through a HyNic-4FB linker (TriLink, #S-9011) 
following the kit instructions. As a validation of the antibody activity post the conjugation, 
purified anti-PD-L1-DNA conjugates from the “TCEP” strategy and the TriLink strategy 
were incubated with PD-L1 overexpressing K562 cells at 4oC for 30 minutes, followed 
by two washes (centrifugation at 400 g x 5 minutes and resuspension in PBS) for flow 
cytometry with a BD LSR II. Anti-PD-L1-DNA conjugate linked through the “TCEP” 
strategy was loaded on DNA-scaffolded PLGA microparticles. PD-L1 overexpressed 
and wildtype K562 cells at 1 million/mL were respectively added with particles at 0.3 
OD550 and incubated for 30 minutes at 37oC, followed by cell nuclei staining with 
Hoechst 33342 (ThermoFisher #62249) and the imaging using the spinning disk 
confocal fluorescence microscope (Nikon Yokogawa CSU-22). 
     His-tag GFP were expressed by Escherichia coli BL21 (DE3) (Novagen) 
transduced with pRSET-EmGFP vector (ThermoFisher, #V35320) in E. coli expression 
medium (MagicMedia, Invitrogen #K6803), and extracted using cell lysis reagent 
(Sigma, #B7435) followed by the purification using nickel-nitrilotriacetic acid affinity 
chromatography (Invitrogen #R90115). The MAL-PEG4-NHS linker (Quanta Biodesign) 
was mixed with GFP at 30-fold molar excess, and incubated at 37°C for 1 hour followed 
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by the size-exclusion chromatography to remove the excess. 3’Thiol-modified 
complementary DNA was decapped using the protocol described above, and reacted 
with modified GFP at 1:10 molar ratio at 37°C for 1 hour followed by 4°C overnight. The 
next day, GFP-DNA conjugates are purified using nickel-nitrilotriacetic acid affinity 
chromatography to remove unconjugated DNA. Protein-DNA conjugates were analyzed 
through SDS-PAGE gel electrophoresis (Genscript #M42012L) with SYPRO Ruby dye 
staining (ThermoFisher #S21900).  
 
Ratiometric control of surface DNA scaffolds with different sequences and the co-
loading of versatile payloads  
3’Thiolated DNA with different sequences were synthesized, namely R, G, and B 
(Fig. 3.7F). Following the conjugation with PLGA10k-PEG5k-Mal (Akina, #AI053), 
polymer-DNA molecules from different sequences were mixed at varying ratios and 
incorporated into the particle fabrication process described above (100 nmol for each 
reactant). Complementary strands to the DNA scaffolds that were pre-conjugated with 
small molecules (e.g. fluorescent dye or biotin, at 1 µM/OD550) or proteins (e.g. GFP or 
antibodies, at 180 nM/OD550), were incubated with particles at 37oC for 30 minutes in 
PBS buffer with 600 mM Na+ and 0.01% Tween-20 supplemented for the surface 
hybridization of payloads. The excess was removed by three washes. For the co-
loading of multiple cargos, the input proportion of each individual one with a specific 
sequence was consistent with its DNA-polymer counterpart input during the particle 
fabrication.  
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   For the loading of biotinylated biomolecules on 3’-biotinylated complementary 
DNA hybridized particles, a large excess of streptavidin (Prozyme #SA10) was added at 
1.1 mg/mL per OD550 and incubated at room temperature for 30 mins, followed by 
three washes. Biotinylated antibody, protein or peptide was added at 180 nM/OD550 
and incubated at room temperature for 30 mins to bind with surface streptavidin 
followed by three washes. 
     Loading efficiencies of different cargos on-surface or in-core were quantified 
through the fluorescence-based assay of dye-labeled DNA strands (5’Quasar570-
compR, 5’Quasar705-compG, 5’Quasar670-compB, Fig. 3.7F), peptides (C-terminus 
FITC-labeled peptide, LifeTein, LLC) or proteins (FITC-labeled human IgG, Sigma 
#SLBW7799), after etching of particles by dimethyl sulfoxide (DMSO) and the dilution 
with 9x volume of water. The fluorescence signal was detected by a plate reader (Tecan 
Spark) and analyzed using a calibration curve with the normalization from OD550. 
Functionalized microparticles with fluorescent labels were imaged through a spinning 
disk confocal fluorescence microscope (Nikon Yokogawa CSU-22), and the size 
distribution was quantified using ImageJ software analysis of images acquired. 
Fluorescent microparticles were also analyzed the concentration using a cell counter 
(Countess II FL AMQAF1000, ThermoFisher). 
 
Surface step-by-step conjugation for payload attaching  
DNA-scaffolded particles were hybridized with 3’amine-modified complementary 
DNA strands at 1 µM/OD550 followed by three washes. A large excess of MAL-dPEG4-
NHS linker (Quanta Biodesign) was added at 30 µM/OD550 and incubated at room 
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temperature for 1 hour followed by three washes to bring maleimide functional groups 
onto DNA scaffolds. To fabricate the control particles with maleimide functional groups 
but without DNA scaffolds, 100 nmol block-co-polymer PLGA-PEG-MAL (Akina #AI053) 
was used to replace the polymer-DNA reaction mixture during the PLGA microparticle 
fabrication described above. Freshly prepared particles with maleimide functional 
groups were then reacted with 3’thiol- 5’Quasar670-modified DNA at 1 µM/OD550 or 
reduced antibody with free thiols (FITC-IgG, Sigma) at 180 nM/OD550 for 1 hour at 
37oC and 4 oC overnight. The next day particles were washed and quantified through 
the fluorescence-based analysis. 
 
DNA scaffolds stability test in DNase and human serum  
PLGA microparticles were hybridized with fluorescently labeled complementary 
DNA strands, followed by human FITC-IgG (Sigma # SLBW7799) loading through 
surface step-by-step conjugation. Particles with and without IgG coverage were 
suspended in the enzyme reaction buffer (Promega #M6101) plus DNase (RQ1 RNase-
free DNase, Promega #M6101) at 5 U per 1 OD550 x 50 µL and incubated at 37oC for 
20 mins, followed by the addition of stop buffer (Promega #M6101) and the 
centrifugation at 10,000 x g for 10 mins to collect the supernatant and pellet for the 
fluorescence-based analysis. Similarly, particles with and without IgG attachment 
together with those hybridized by GFP-DNA conjugates were suspended in human 
serum (bioWORLD #v13081400) and incubated for 1 hour at 37oC, followed by the 
centrifugation to collect the supernatant and pellet for the fluorescence-based analysis.  
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Cell lines and culture  
K562 human myelogenous leukemia cells (ATCC #CCL-243) and A375 human 
malignant melanoma cells (ATCC #CRL-1619) were used in T cell killing experiments. 
K562 and A375 were lentivirally transduced to stably express human HER2, PD-L1 and 
GFP. All cell lines were FACS-sorted for expression of the transgenes. A murine 
macrophage cell line J77A4.1 (ATCC TIB-67) was used for particle uptake assay. K562 
cells were cultured in Iscove's Modified Dulbecco's Medium (Corning #10-016-CV) with 
10% fetal bovine serum (FBS, UCSF Cell Culture Facility) and gentamicin (UCSF Cell 
Culture Facility). A375, J77A4.1 cells and Lenti-X 293T packaging cells (Clontech 
#11131D) were cultured in Dulbecco's Modified Eagle's Medium (Gibco #10569-010) 
with 10% FBS. 
 
Macrophage uptake assay  
Biotin-modified “self”-peptide (biotin-miniPEG-
GNYTCEVTELTREGETIIELK[Lys(FITC)], LifeTein) was loaded onto streptavidin-coated 
PLGA microparticles using the protocol described above. The streptavidin of the control 
particles without “self-peptide” were labeled with NHS-fluorescein (ThermoFisher 
#46409) at 6 µM/OD550 for 1 hour at room temperature, followed by three washes. 
Murine macrophage cell line J77A4.1 (ATCC) grown on glass bottom chamber slides 
(Thermo Scientific #154526) was treated with lipopolysaccharides (Sigma #L4391) at 
100 ng/mL for overnight. On the next day, “self”-peptide loaded particles and control 
particles were added at 0.03 OD550 x 200 µL and incubated at 37oC for 1 hour. Cells 
were then washed three times with PBS to remove un-internalized particles and fixed 
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using 4% paraformaldehyde (Electron Microscopy Sciences #15710) for 20 minutes. 
After three washes, cells were imaged using the spinning disk confocal fluorescence 
microscope (Nikon Yokogawa CSU-22). Images were analyzed for cell fluorescence 
signal using ImageJ software. 
 
Primary human T cell isolation and culture  
Primary CD4+ and CD8+ T cells were isolated from anonymous donor blood 
after apheresis by negative selection (STEMCELL Technologies #15062 and #15063). 
T cells were cryopreserved in RPMI-1640 (Corning #10-040-CV) with 20% human AB 
serum (Valley Biomedical, #HP1022) and 10% DMSO. After thawing, T cells were 
cultured in human T cell medium consisting of X-VIVO 15 (Lonza #04-418Q), 5% 
Human AB serum, and 10 mM neutralized N-acetyl L-Cysteine (Sigma-Aldrich #A9165) 
supplemented with 30 units/mL IL-2 (NCI BRB Preclinical Repository) for all 
experiments.  
  
Antibody staining and flow cytometry analysis  
All antibody staining for flow cytometry was carried out in wells of round bottom 
96-well tissue culture plates. Cells were pelleted by centrifugation of plates for 4 
minutes at 400 x g. Supernatant was removed and cells were resuspended in 50 μL 
PBS containing the fluorescent antibody of interest. Cells stained 25 minutes at 4°C in 
the dark. Stained cells were then washed two times with PBS and resuspended in fresh 
PBS for flow cytometry with a BD LSR II. All flow cytometry data analysis was 
performed in FlowJo software (TreeStar). 
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AICE-mediated activation of human primary T cells for ex vivo expansion  
AICEs were synthesized with PLGA microparticles functionalized with anti-CD3 
antibody (Bio X Cell #BE0001-2, attached to 3’NH2-5’Qusar670-modified compB), and 
anti-CD28 antibody (Bio X Cell #BE0248, attached to 3’NH2-5’FAM-modified compR) at 
varying ratios from 1:5, 1:3, 1:1, 3:1 to 5:1 according to the method described above. 
After thawing and 24-hour recovery in culture, 1.4 x 105 CD4+/CD8+ human primary T 
cells in 200 µL medium were added with AICEs at 0.11 OD550 (approximately 2.5 AICE 
to 1 cell), or CD3/CD28 Dynabeads at a 1:2.5 cell:bead ratio (Life Technologies 
#11131D) for 4 days. CD8+ T Cells were imaged through the spinning disk confocal 
microscope (Nikon Yokogawa CSU-22) one day after AICE addition. CD4+ and CD8+ T 
Cells numbers were quantified using a cell counter (Countess II FL AMQAF1000, 
ThermoFisher) every other day from day 6 to day 14 after AICE activation. Fresh IL-2 
containing medium was supplemented to maintain the cell concentration between 0.5-
1.5 million per mL. On day 14, T cell phenotype was studied by flow cytometry using the 
following antibodies: anti-CCR7 (BD #561271), anti-CD45RA (BD #562885), anti-LAG-3 
(BD #565720), anti-TIM-3 (BD #565558), anti-PD-1 (Biolegend #329936). 
    Anti-IL-2 clone #5355 (ThermoFisher #MA523696) was biotinylated using NHS-
PEG4-biotin (Quanta Biodesign #10200) at 30 x molar excess, with the incubation at 
37oC for 1 hour followed by size exclusion chromatography (ThermoFisher #89882) to 
purify. Streptavidin-coated PLGA microparticles were incubated with biotinylated anti-IL-
2 at 20 nM/OD550 and IL-2 (NCI BRB Preclinical Repository) at 30 nM/OD550 at room 
temperature for 30 minutes, and washed twice. Surface-bound IL-2 on particles were 
supplemented at 0.1 OD550/mL to AICE [3:1]-treated T cells and replenished to 
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maintain the cell concentration at 0.5-1.5 million per mL, as a comparison to free IL-2 
supplementation at 30 units/mL. 
 
Transduction of synthetic Notch CAR T cells  
The binding domains of LaG17 nanobody (Roybal et al., 2016) and GCN4 (PNE) 
scFv (Rodgers et al., 2016)  were cloned into synNotch receptors with Gal4 DNA-
binding domain VP64 as a synthetic transcription factor (Roybal et al., 2016). The 
response element plasmids was modified from the pHR’SIN:CSW vector with five 
copies of the Gal4 DNA binding domain, a HER2-CAR in the multiple cloning site 
downstream of the Gal4 response elements, and a PGK promoter that constitutively 
drives mCherry expression to easily identify transduced T cells (Roybal et al., 2016). All 
constructs were cloned via InFusion cloning (Takara Bio #638910). Pantropic VSV-G 
pseudotyped lentivirus was produced via transfection of Lenti-X 293T cells with a 
pHR’SIN:CSW transgene expression vector and the viral packaging plasmids 
pCMVdR8.91 and pMD2.G using Fugene HD (Promega #E2312). Primary T cells were 
thawed the same day and, after 24 hours in culture, were stimulated with Human T-
Activator CD3/CD28 Dynabeads (Life Technologies #11131D) at a 1:2.5 cell:bead ratio. 
At 48 hours, viral supernatant was harvested and the primary T cells were exposed to 
the virus for 24 hours. At day 5 after T cell stimulation, Dynabeads were removed and 
the T cells expanded until day 12 when they were rested and could be used in assays. 
T cells were sorted for assays with a FACs ARIA II on day 5 post T cell stimulation.  
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In vitro stimulation of synNotch T cells through AICEs  
2.5 x 104 synNotch CD4+ or CD8+ T cells were co-cultured with target cancer 
cells at a 1:1 ratio, with the addition of AICE at 0.075 OD550 x 200 µL medium (100 µL 
T cell medium + 100 µL cancer cell medium) (unless otherwise specified). Dual antigen 
(GFP and HER2) positive target cells (A375 and K562) were used as positive controls. 
After mixing, cells were centrifuged for 2 min at 300 x g to initiate interaction of the cells. 
After 24 hours, the co-culture from CD8+ T cells were stained with anti-CD69 antibody 
(BD #562884) and analyzed by flow cytometry (BD LSR II), and also imaged through 
the spinning disk confocal microscope (Nikon Yokogawa CSU-22). After 48 hours, 
cytokine concentration in the supernatant was measured by IL-2 ELISA (for CD4+ T 
cells, eBiosciences #BMS2221HS) and Interferon-g (IFN-g) ELISA (for CD8+ T cells, 
ThermoFisher #KHC4021). 
     To quantify target cell killing, 2.5 x 104 A375 cells were seeded on flat-bottom 96-
well tissue culture plate (Falcon #353072) and cultured for 8 hours, followed by the 
addition of 2.5 x 104 CD8+ T cells and AICE at 0.075 OD550 x 200 µL final (unless 
otherwise specified). After 1-3 days, cells were gently washed with PBS for 2 times, and 
analyzed for cell viability using PrestoBlue Cell Viability Reagent (Invitrogen #A13262).  
 
IVIS imaging of IR dye-labeled AICE in mice tumors  
NH2-modified PLGA polymer (LG 50:50, Mw 30,000-40,000 Da) dissolved in 
DMF was reacted with IR800CW-NHS Ester (Li-COR #P/N 929-70020) at 30-fold molar 
excess at room temperature for 1 hour, followed by repeat 70%-ethanol precipitation 
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and DMF re-dissolving to remove the unconjugated dye. 1 mg of IR800CW-labeled 
polymer was incorporated in the emulsion protocol for DNA-scaffolded (G strand) PLGA 
microparticles, and 5’Quasar705-modified compG strand was hybridized on surface. 
NSG mice (Jackson Laboratory #005557, female, ~8-12-weeks old) were implanted with 
xenograft tumors - 5 x 106 K562 tumor cells subcutaneously on the left and right flank. 
10 days after tumor implantation, 50 µL particles at 100 OD550 were injected 
intratumorally, and imaged under IVIS 100 preclinical imaging system (Xenogen 
#124262) every 3-4 hours for the first 48 hours and every 8 hours for the rest of the 
week. Images are analyzed using Living Image Software (PerkinElmer).  
 
In vivo tumor targeting  
NSG mice (Jackson Laboratory #005557, female, ~8-12-weeks old) were 
implanted with two identical xenograft tumors - 5 x 106 HER2+ K562 tumor cells 
subcutaneously on the left and right flank. Seven days after tumor implantation, human 
primary CD4+ (4 x 106) and CD8+ T cells (4 x 106) were injected intravenously into the 
tail vein of the mice. These T cells were either untransduced (control) or engineered 
with the anti-GFP synNotch Gal4VP64 receptor and the corresponding response 
elements regulating a-HER2 4-1BBz CAR expression. On the same day, AICE-GFP 
particles were injected intratumorally at one side of the two flanks with 50 (or 10) OD550 
x 50 µL per dose, leaving the other as the control. Three additional doses of AICE were 
injected into the same tumor every 4 days or starting as the tumor grew over 500 mm3 
in volume. Tumor size was monitored via caliper over 20 days after T cell injection. Mice 
were euthanized as any tumor reached 20 mm in diameter or became ulcerated. 
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    Remaining tumors from contralateral flank and early euthanized mice were 
collected and fixed in 4% paraformaldehyde (Electron Microscopy Sciences #15710) 
overnight, followed by the dehydration in 30% sucrose (Sigma #S9378) for 1-2 days 
until sunk. Tumors were then snap-frozen in OCT (Tissue-Tek) to produce cryosections. 
Sections were stained with anti-CD3 antibody (Biolegend #344811) in 1% BSA/PBS for 
1 hour and washed three time, followed by the imaging with the spinning disk confocal 
fluorescence microscope (Nikon Yokogawa CSU-22). 
 
Statistical analysis  
Statistical analysis were preformed using GraphPad Prism software. All values 
and error bars are mean ± s.d., except where indicated differently. Two-tailed paired t 
test, one-way ANOVA test, one site-specific binding model fit, and fourth order 
polynomial model fit were performed where appropriate. 
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Figure 3.1. The synthesis of polymeric micro-/nano- particle with surface DNA 
scaffolds for therapeutic protein presentation 
 
(A) Schematic of biodegradable polymeric particles with versatile therapeutic protein 
loading through surface DNA scaffolds, and their use as artificial immune cell engager 
(AICE) for ex vivo T cell expansion and in vivo activation control.  
 
(B) Diagram of DNA presentation on polymeric particles through the emulsion protocol.  
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(C) Representative denatured PAGE electrophoresis gel image of the DNA-polymer 
conjugation reaction at different stoichiometry, and the quantification by densitometry 
analysis. Data are mean ± s.d. (n = 3 independent experiments), and the curve was 
fitted by Hill slope specific binding model.  
 
(D) Hybridized DNA scaffold on PLGA particles made from DNA-polymer conjugates of 
different coupling efficiencies, versus surface conjugation of dye-labeled DNA after 
particle fabrication. Data are mean ± s.d. (n = 6 independent samples from 3 
independent experiments), and P values were determined by one-way analysis of 
variance (ANOVA) and Tukey’s tests.  
 
(E) Representative size distribution of DNA-decorated PLGA particles from different 
fabrication protocols described in Figure S1j (n = 3 independent experiments). Green 
and blue curve are through dynamic light scattering assay; orange curve is from ImageJ 
software analysis of confocal fluorescence images. 
  
(F) Representative SEM image of PLGA particles with average size at 1484 nm and 669 
nm (n = 3 independent samples). White arrow points to the particle with concave shape 
at one side. Scale bar, left image - 2 µm, right image - 0.5 µm.  
 
(G) Representative images of PLGA microparticles with peptides and oligonucleotides 
in the core and DNA scaffold on the surface (n = 2 independent experiments). Scale 
bar, 3 µm.  
 
(H) Representative image of DNA-scaffolded microparticles composed of PLA polymer 
(n = 3 independent experiments). Scale bar, 5 µm. 
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Figure 3.2. The multi-functionalization of DNA-scaffolded PLGA microparticles 
 
(A) Schematic of two strategies of antibody loading on the particle surface.  
 
(B) Quantification of FITC-labeled IgG loading density by the two strategies depicted in 
(A). Data are mean ± s.d. (n = 3 independent experiments), and P values were 
determined by two-tailed paired t test.  
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(C) Representative confocal microscopy images of anti-PD-L1 antibody loaded PLGA 
microparticles co-incubation with PD-L1 +/- K562 cells for 1 hour (n = 3 biologically 
independent samples per group).  Scale bar, 10 µm.  
 
(D) Schematic of the control of DNA scaffolds with distinct sequences at intended ratios 
and its confirmation through corresponsive dye-labeled complementary DNA 
(compDNA) hybridization test.  
 
(E) Representative confocal microscopy images of PLGA microparticles with DNA 
scaffolds of different sequence compositions after hybridization with corresponding dye-
labeled compDNA. The merged images of particles agreed well with the theoretically 
integrated color at different input ratios. Scale bar, 5 µm.  
 
(F) DNA duplexes of different sequences on particles by the fluorescence-based 
analysis. Data are mean ± s.d. (n = 5 independent samples from 2 independent 
experiments).  
 
(G) Loading density of three different proteins sharing the same surface guided by DNA 
scaffold compositions, relative to their individual maximum without sharing. Data are 
mean ± s.d. (n = 3 independent experiments).  
 
(H) Schematic of DNA scaffold integrity on the particle surface with and without IgG 
coverage, in the presence of DNase.  
 
(I) Intact DNA duplexes on PLGA microparticles after co-incubating with large excess of 
DNase for 20 minutes at 37oC. Data are mean ± s.d. (n = 3 independent experiments), 
and P values were determined by two-tailed paired t test.  
 
(J) Intact DNA duplexes with different attachments on PLGA microparticles after 
incubation in human serum for 1 hour at 37oC. Data are mean ± s.d. (n = 5 independent 
samples from 2 independent experiments) and P values were determined by one-way 
ANOVA and Tukey’s tests.  
 
(K) Representative confocal microscope images of macrophages treated with particles 
with and without “Self”-peptide presentation (n = 3 biologically independent samples per 
group). Scale bar, 10 µm. 
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Figure 3.3. AICE with ratiometrically controlled moieties for human primary T 
lymphocytes ex vivo expansion 
 
(A) Schematic of AICE (in this figure PLGA microparticles loaded with anti-CD3 and 
anti-CD28 antibodies of varying ratios from [1:5] to [5:1]) for primary T cell expansion, 
compared with commercial available T cell expander Dynabeads (Invitrogen).  
 
(B) Representative confocal microscopy images of human primary CD8+ T cell co-
incubated with AICE [1:1] for overnight, showing AICE-induced cell clumps (n = 3 
biologically independent samples). Scale bar, 10 µm.  
	 157	
(C) Cell yield of CD4+ and CD8+ T cells at day 14 after activation by AICE with anti-
CD3 and anti-CD28 antibodies at different ratios, relative to Dynabeads. Data are mean 
± s.e.m., and P values were determined by one-way ANOVA test for linear trend (n = 3 
independent donors of two independent experiments).  
 
(D) Gating strategy through CCR7 and CD45RA expression levels for distinguishing 
cells at specific differentiation stages: naïve, central memory (CM), effector memory 
(EM), and effector memory RA (EMRA).  
 
(E) Differentiation profile of T cells 14 days after activation by AICE of varying ratios of 
surface moieties. Data are mean of n = 3 independent donors.  
 
(F) Growth curve of primary CD8+ T cells from three different donors upon the activation 
by AICE [3:1], compared to Dynabeads control. Data are mean ± s.e.m. (n = 3 
independent donors of two independent experiments).  
 
(G) Exhaustion phenotype of CD4+/CD8+ T cells from 3 individual donors 14 days after 
activation by AICE [3:1] and Dynabeads.  
 
(H) Schematic of IL-2 presented on particles through its antibody (clone5355) that 
exposes the epitope for b and g units of its receptor on T cells, promoting the cell 
proliferation.  
 
(I) Cell yield of primary CD4+ T cells activated by AICE [3:1] with surface-bound IL-2 or 
free IL-2 at day 8 and 14, relative to the Dynabeads method. Data are mean ± s.d. (n = 
2 independent donors).  
 
(J) Growth curve of CD4+ primary T cells from two different donors treated with AICE 
[3:1] together with surface bound IL-2 or free IL-2, compared to Dynabeads control. 
Data are mean of n = 2 technical replicates.  
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Figure 3.4. Activation of AND-gate engineered human primary T cells through 
AICE functionalized with priming antigens for the induction of CAR toxicity 
 
(A) Schematic of T cell engineering for dual antigen AND-gate targeting, and its priming 
by synthetic antigen (herein GFP) presented by AICE to trigger HER2-CAR guided 
killing, alternative to existing strategy of dual antigen target cell killing.  
 
(B) Expression level of CD69 as an early activation marker for CD8+ synNotch/CAR T 
cells after 24 hours of co-incubation with AICE and HER2-overexpressed A375 target 
cells, compared to the treatment of target cell K562 with GFP and HER2 co-expressed 
(n = 2 independent experiments).  
 
(C) IL-2 and IFN-g secretion levels by primary CD4+ and CD8+ T cells 48 hours after 
AICE and HER2-overexpressed target cell A375 co-incubation. Data are mean ± s.d. (n 
= 2 technical replicates from 4 biologically independent samples).  
 
(D) Representative confocal fluorescence microscopy image of the co-incubation of 
CD8+ synNotch CAR-T cells, GFP-presenting AICE and HER2-overexpressing A375 
cells after 24 hours (n = 2 independent experiments). Scale bar, 10 µm. The arrow 
points to a dead A375 cell.  
	 159	
(E) Representative forward and side scatter flow cytometry plots after 24-hour co-
culture of HER2-expressing A375 and CD8+ synNotch CAR-T cells in the presence and 
absence of AICE (n = 3 independent experiments). The T cells fall within the blue gate, 
and the target A375 cells are in the orange gate.  
 
(F) Cell survival test of target A375 cells 48 hours after co-culture of AICE and synNotch 
CAR-T cells. Data are mean ± s.d. (n = 6 independent experiment with 4 independent T 
cell donors), and P values were determined by one-way ANOVA and Tukey’s tests. 
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Figure 3.5. Selective tumor killing in vivo by local activation of synNotch CAR-T 
cells using AICE 
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(A) IVIS fluorescence imaging of IR dye-labeled AICE (Quasar705 on surface DNA and 
IR800CW in core) in subcutaneous K562 tumors of NSG mice over 6 days (n = 5 mice). 
Left tumors are injected with AICE made of PLA; right tumors are injected with AICE 
made of PLGA.  
 
(B) Quantification of the average signal intensity at the tumor area (right tumor with 
AICE-PLGA) for the full set IVIS images acquired over 6 days in (A). Lines are the mean 
signal from n = 5 mice.  
 
(C) Schematic of two tumor model for selected clearance by AICE-primed synNotch 
CAR-T cell activation through local intratumoral injection, and treatment timeline.  
 
(D) Tumor volume of AICE-injected tumor versus contralateral tumor over 19 days after 
combinatorial treatment of untransduced primary T cell and GFP-coated AICE. Data are 
mean  ± s.e.m. (n = 6 mice), and P values were determined by two-tailed paired t test.   
 
(E) Tumor volume of AICE-injected tumor versus the contralateral tumor over 19 days 
after combinatorial treatment of synNotch CAR-T cell and GFP-coated AICE. Data are 
mean  ± s.e.m. (n = 8 mice, and 2 mice met the euthanasia criteria at day 13-15), and P 
values were determined by two-tailed paired t test.  
 
(F) Representative image of mice injected i.v. with synNotch CAR-T cells, showing 
diminished tumor on AICE injection site but growing tumor at the contralateral flank.  
 
(G) Tumor volume of individual mice shown in (E).  
 
(H) Representative images of fixed staining of CD3+ T cells in tumors collected from 
mouse 8 in (G), which is sacrificed in earlier date meeting euthanasia criteria (n = 10 
technical replicates). Scale bar, 50 µm. 
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Figure 3.6. Optimization of DNA scaffolds on polymeric particles 
 
(A) Representative denatured TBE-Urea PAGE gel image of different polymer-DNA 
conjugates yielded from the conjugation of maleimide (Mal)-modified polymer at 100 µM 
with thiol-modified DNA 17mer at 20 µM (n = 3 independent experiments). White 
arrows, product bands. Modified polymers tested are Mal-PCL(polycaprolactone, Mw 
2,000)-Mal6, PCL(Mw 4,000)-PEG(polyethylene glycol, Mw 2,000)-Mal (Akina #AI082), 
PLGA(poly(lactic-co-glycolic acid), 50:50, Mw 10,000)-PEG(Mw 5,000)-Mal (Akina 
#AI053) and PLGA(Mw 20,000)-PEG(Mw 5,000)-Mal (NSP #12191).  
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(B) Hybridized surface DNA on PLGA microparticles (target 1-2 µm in diameter) by 
incorporation of different polymer linkers for particle fabrication. Data are mean ± s.d. (n 
= 3 independent experiments). The polymer-DNA conjugate made from Mal-PCL(2k)-
Mal did not yield particles at the desired size, while for PCL(4k)-PEG(2k)-Mal, 0.2% 
PVA (polyvinyl alcohol) was required during the fabrication.  
 
(C-D) Denatured TBE-Urea PAGE gel image of polymer-DNA reaction 
(DNA:polymer=1:1) at varying reactant concentrations (C) and 25mer DNA (D), 
quantified by densitometry analysis (n = 1 for each variable). Reactant at 400µM formed 
obvious aggregates, which may over-estimate the conjugation efficiency, and 25 mer 
yielded lower conjugation efficiency than 17 mer (Fig. 1c). Thus, reactants at 200 µM 
and DNA-17mer was selected for later reactions.  
 
(E-G) Linear regression of the dilution (E), particle concentration by Cell Counter 
(ThermoFisher) (F) and dry weight (G) of PLGA microparticles to optical density at 550 
nm (OD550). n = 1 for each variable in (C-G).  
 
(H-I) Hybridized DNA scaffold on PLGA microparticles from different hybridization 
conditions (H) and lyophilization (lyo) treatment (I). Data are mean ± s.d. (n = 3 
independent samples).  
 
(J) Schematic of the size control of DNA-decorated PLGA particles by varying key 
parameters in the fabrication protocol. The size can be tuned through the varying of 
polymer concentration, the two-phase volume and ratio, and the employment of other 
surfactants (i.e. PVA).  
 
(K) Schematic of the double-emulsion protocol to incorporate biomolecules in the core 
of DNA-scaffolded particles, where small volume of peptides and oligonucleotides 
(oligo) are emulsified in the organic solvent prior to the polymer-DNA emulsion.  
 
(L) Fluorescence quantification of dye-labeled peptide and oligo in the core, compared 
to surface-hybridized DNA scaffolds. Data are mean ± s.d. (n = 5 from two independent 
experiments).  
 
(M) The emulsion protocol for DNA-scaffolded microparticles made of polylactic acid 
(PLA), and their size distribution by ImageJ software analysis of confocal fluorescence 
images of particles hybridized with dye-labeled complementary DNA strands (n = 6 
technical replicates of 3 independent samples). The curve is a non-linear fit by fourth 
order polynomial model.  
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Figure 3.7. Surface functionalization strategies for various protein surface 
conjugates 
 
(A) Quantification of the surface conjugation of FITC-labeled IgG to the functional 
groups present on PLGA microparticles with and without DNA scaffold at different 
densities. Data are mean ± s.d. (n = 3 independent experiments).  
(B) SDS-PAGE gel image of DNA-IgG (anti-PD-L1) conjugates linked through different 
chemistries: TriLink (to 3’NH2-5’Quasar570 DNA 22mer) versus “TCEP” (to 3’NH2-
5’Quasar705 DNA 22mer). Optimal DNA to IgG ratio was essential for the protein 
activity through the TriLink strategy, and protein aggregation was observed at higher 
DNA to IgG ratio. TCEP strategy led to some IgG fractionation, but can be minimized 
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through lowering TCEP to IgG ratio. Unattached DNA were removed by affinity 
chromatography purification prior to the surface hybridization. Data represent n = 3 
independent experiments.  
 
(C) Flow cytometric analysis of PD-L1 overexpressing K562 stained with DNA-antibody 
(anti-PD-L1) linked by the TriLink and “TCEP” strategies, in comparison to commercial 
PE-labeled anti-PD-L1 (n = 1 for each variable).  
 
(D) Conjugation strategies of complementary DNA to proteins and antibodies. The hinge 
region of IgG or Fc-tagged proteins can be partially reduced to expose thiols for 
tethering with amine-modified DNA through the Mal-PEG4-NHS linker; proteins can be 
linked through primary amines to thiol-modified DNA via the Mal-PEG4-NHS linker; 
biotinylated proteins or antibodies can be attached on particle surface through the 
streptavidin bridge. The “TCEP” strategy was extensively used in this work for many 
antibodies to generate DNA-protein conjugates without activity loss. In terms of 
therapeutic proteins other than antibodies, a commonly found Fc-tag on commercial 
proteins can be utilized with the same chemistry; for certain protein sensitive to TCEP 
reduction, an antibody to its Fc-tag or non-essential site can be first incorporated as the 
surface dock; otherwise, proteins can also be modified on their primary amines, but the 
excess ratio of the linker needs to be optimized to maintain the activity.  
 
(E) SDS-PAGE gel image of GFP-DNA conjugates synthesized through the linking of 
primary amine to thiol-modified DNA with different linker excess. Data represent n = 2 
independent experiments.  
 
(F) Sequence of DNA strands (G, R and B) that are attached to polymers, and their 
respective complementary strands (compG, compR and compB). *: phosphorothioated 
DNA base.  
 
(G) Confocal fluorescence microscopy images of PLA microparticles with DNA scaffolds 
of different sequence compositions post hybridization with the corresponding dye-
labeled compDNA. The merged images of particles agreed well with the theoretically 
integrated color (upper right) at different input ratios.  
 
(H) DNA duplexes of different sequences on PLA particles by fluorescence-based 
quantification. Data are mean ± s.d. (g and h are from n = 2 independent experiments).  
 
(I) Fluorescence-based quantification of biotinylated peptide loaded through streptavidin 
on DNA scaffolds (G), with and without the co-loading of IgG on DNA scaffolds of a 
different sequence (R). Data are mean ± s.d. (n = 3 independent samples).  
 
(J) Fluorescence-based quantification of particles in individual J774A.1 macrophage 
cells through ImageJ software analysis. Data are mean ± s.d. (n = 3 biologically 
independent samples per group) and P value was determined by two-tailed paired t test. 
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Figure 3.8. Activation of human primary T lymphocytes by functionalized AICE for 
ex vivo expansion 
 
(A) Cell yield of CD4+ T cells at day 8 and 14 after activation by AICE with CD3 and 
CD28 antibodies at different ratios, relative to Dynabeads. Data are mean ± s.e.m. (n = 
3 independent donors of two independent experiments).  
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(B) Differentiation profile of T cells from 3 individual donors at 14 days after activation 
by AICE with varying ratios of surface stimulatory moieties.  
 
(C) Gating strategy of the exhausted cell population based on expression levels of LAG-
3, PD-1 and TIM-3 on expanded CD4+/CD8+ cells 14 days after activation by AICE 
[3:1] and Dynabeads.  
 
(D) Exhaustion phenotype of CD4+/CD8+ T cells from 3 individual donors 14 days after 
activation by AICE [3:1] and Dynabeads.  
 
(E) Binding curve of IL-2 to PLGA microparticles coated with IL-2 antibodies. Data are 
mean ± s.d. (n = 4 technical replicates from 2 independent samples), and the curve is a 
nonlinear fit by the one site-specific binding model.  
 
(F) Viable CD8+ human primary T cells over time with different doses of surface bound 
IL-2 on PLGA microparticles versus free IL-2. The amount of free IL-2 is equivalent to 
particles between 0.004 OD and 0.01 OD. Data are mean of n = 2 technical replicates.  
 
(G) Growth curve of CD8+ primary T cells from two different donors treated with AICE 
[3:1] together with AICE-bound IL-2 or free IL-2 at equivalent dose, compared to 
Dynabeads with free IL-2 control. Data are mean of n = 2 technical replicates.  
 
(H) Levels of LAG-3, PD-1 and TIM-3 for CD4+ T cells of two different donors 14 days 
after activation by AICE [3:1] together with AICE-bound IL-2, or free IL-2. 
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Figure 3.9. Activation of human primary synNotch CAR-T cells for AND-gated 
target cell toxicity using AICE coated with priming antigens 
 
(A) IL-2 secretion levels by primary synNotch CAR CD4+ T cells 48 hours post co-
incubation of A375-HER2 and AICE with different GFP densities and different particle 
doses. Total amount of antigen presented by AICE particles with “Fully dense” was 
equal to “1/3 dense x 3”. The antigen density on AICE matters more than the total 
amount of antigen for synNotch CAR-T cell activation. Data are mean ± s.d. (n = 2 
technical replicates from 4 biologically independent samples).  
 
(B) IFN-g secretion concentration from primary CD8+ T cells 48 hours post co-
incubation of AICE and A375-HER2 versus dual antigen target cells A375-
GFP+/HER2+. Data are mean ± s.d. (n = 4 technical replicates from 4 biologically 
independent samples), and P value was determined by two-tailed paired t test.  
 
(C-F) Cell survival study of target A375-HER2 cells from co-culturing of AICE-primed 
synNotch CAR-T cells, with a series of conditions, including varying densities of priming 
antigen on AICE (C), different doses of AICE to T cells (D), different duration of 
treatments (E) and varying T cell to target cell ratios (F). Data are mean ± s.d. (n = 4 
biologically independent samples).  
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(G) Cell survival test of target A375-HER2 cells treated with a different type of synNotch 
CAR-T cells responsive to PNE peptide present on AICE after 48 hours of co-culture. 
Data are mean ± s.d. (n = 4 biologically independent samples). 
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Figure 3.10. In vivo half-life of AICE with different compositions and their priming 
of synNotch CAR-T cells for selective tumor clearance 
 
(A) IVIS near-infrared fluorescence imaging of AICE in vitro with Quasar705 on surface 
and IR800CW in core. The two dyes can be imaged at the same time without cross-
interference.  
 
(B) IVIS fluorescence imaging of labeled AICE in subcutaneous K562 tumors of NSG 
mice at day 4 and day 6 (n = 5 mice). Left tumors are injected with AICE made of PLA; 
right tumors are injected with AICE made of PLGA.  
 
(C-E) Quantification of the average fluorescence signal of surface coatings at the tumor 
area over 6 days, from the injection of PLGA microparticles with and without IgG 
coverage (C), PLA microparticles with and without IgG coverage (D), and microparticles 
made of PLGA versus PLA (E). Half-life of the surface coatings of AICE in K562 tumors 
of NSG mice was not affected by the polymer composition (between PLGA and PLA) 
and surface IgG coverage. Lines are the mean signal from n = 5 mice.  
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(F) Quantification of CD3+ T cell numbers in the stained tumor sections from mouse 8 
shown in Fig. 5h (n = 10 technical replicates). 
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Chapter 4 – Summary and Conclusions 
 
Catching precision therapy up to precision informatics – achieving specific 
cancer targeting with combinatorial antigen-sensing synNotch T cells 
 The motivation behind this work was to develop effective yet safe cancer 
treatments. Despite the impressive advances in modern medicine, there is still a 
significant lack of potent cancer therapies that do not also come with severe side 
effects. Cancer cells originate from our own healthy cells and “look” extremely similar, 
which has made the development of drugs to specifically kill only cancer cells extremely 
difficult. Traditional small molecule and biologic therapeutics have limited capacity to 
interrogate potential target cells and to discriminate between cancerous and healthy 
cells. However, this type of discrimination is exactly what is required of a therapeutic to 
achieve the desired anti-disease effects without also causing toxic side effects by 
harming normal tissues. Engineered T cell therapies have recently taken oncology by a 
storm, and cell-based therapies present unprecedented opportunities to develop “smart 
drugs” that potently kill tumor cells but ignore healthy cells. CAR T cells have proven to 
be immensely powerful and capable of both eliminating cancer burdens and obliterating 
healthy organs with ON-target OFF-tumor antigen expression, which demonstrates the 
vast therapeutic potential if these cells’ formidable cytotoxicity can be precisely targeted. 
The work presented here describes approaches to program therapeutic T cells 
with combinatorial antigen recognition circuits that take advantage of living cells’ 
computational potential by integrating information from multiple independently signaling 
receptors. Additionally, a biomaterial system is developed to enable dynamic user-
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control of cells expressing these circuits in vivo throughout the course of treatment. 
SynNotch T cells provide a unique opportunity to translate advances in cancer (and 
healthy tissue) omics data analysis to therapies with more precise tumor targeting. Up 
to this point, our improved understanding of molecular cancer pathology has not led to 
more precise therapies because we have lacked the engineering tools to exploit these 
multifaceted antigen signatures. The synNotch receptor system enables engineering 
therapeutic cells with unparalleled decision making ability. Given the computational 
power of these synNotch T cells, now the main engineering limit to combinatorial 
antigen recognition of cancer may be the availability of exquisitely antigen-specific 
binding domains (e.g. scFv) to use as inputs in circuits.  
 
Diversity of novel antigen-sensing circuits to address unmet needs 
 We have shown that it is possible to engineer synNotch T cells with a diverse 
array of combinatorial antigen recognition circuits with novel targeting abilities. By 
enhancing the capabilities of 2 receptors circuits and introducing 3 receptor circuits, we 
have expanded the scope and specificity of antigen signatures that can be targeted with 
therapeutic T cells. The novel circuits were designed to meet critical unmet needs for 
robust tumor-specific killing. 
 Given that most cancer antigens are intracellular proteins, we reasoned that 
AND-gate T cells would be more useful if they could sense internal antigens. Previous 
AND-gate T cell strategies have been restricted to cell surface antigens. We have 
shown that internal antigens can be used as either the priming or killing input in dual-
antigen synNotch AND-gate circuits. The general concept of utilizing synNotch 
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receptors to regulate TCR expression can be applied to any TCR with potential ON-
target OFF-tumor cross-reactivity. Our demonstration that inNotch receptors can be built 
to target internal antigens presented as pMHC increases the pool of antigens available 
to induce transcriptional regulation via the synNotch system. While it is extremely 
challenging to target single amino acid mutations in MHC-presented peptides, the 
development of inNotch receptors targeting neo-antigen pMHCs could be particularly 
useful as tumor-specific priming antigens, similar to EGFRvIII. We hope that this work 
will help to encourage the development of single chain binding domains (scFv, 
nanobody, single chain TCR variable [scTv]) targeting disease-related pMHC antigens. 
In our experience building candidate inNotch receptors many published pMHC-targeted 
scFvs displayed non-specific reactivity with the MHC in the absence of target peptide, 
which highlights the need to develop new binding domains with improved specificity.  
 To enhance the precision of tumor targeting, we demonstrate that logic-gated 
synNotch T cells can sense up to 3 antigens, integrating positive and negative 
regulation. The ability to engineer T cells with two orthogonal synNotch receptors is key 
to building 3-input circuits also incorporating a killing receptor (CAR/TCR). We 
engineered 3-input AND-gate T cells by using two synNotch receptors to control 
expression of separate parts of a split CAR with specificity for a third antigen. This 
general concept of utilizing synNotch receptors to regulate expression of split receptor 
components should enable building 3-input AND-gate incorporating alternate split killing 
receptor systems.  
 To generate a NOT-gate capable of overriding positive killing signals, we built a 
synNotch-induced apoptosis system called offNotch. We showed that offNotch prevents 
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killing of cells expressing its target antigen by inducing T cell apoptosis so that there are 
insufficient T cell numbers to cause appreciable damage. One key factor that became 
apparent in this work is the balance of signaling strength between the two orthogonal 
synNotch receptors within the same T cell. If two orthogonal synNotch receptors do not 
have equal signaling strength (e.x. due to scFv affinity or synthetic TF efficiency), then 
much care must be taken to match different payloads with either stronger or weaker 
synNotch receptors to achieve the desired inducible cell behaviors. offNotch can be 
integrated with synNotch AND-gates to generate 3-input circuits that can prevent toxic 
reactions with healthy cells identified as at risk of cross-reactivity.  
 To help combat issues of antigen heterogeneity and escape, we also showed 
that dual-antigen receptors could be integrated into synNotch circuits. Other groups 
have developed dual CARs capable of killing cells expressing either target antigen, and 
we found that synNotch-induction of these dual CARs could lead to robust killing of 
heterogeneous tumors. To further enhance the flexibility of our circuits, we 
demonstrated that dual synNotch receptors could be built to target antigens in an OR-
gate fashion. These dual synNotch receptors can be used to drive CAR expression, 
generating another circuit option poised to tackle heterogeneous tumors and target 
cancers at risk of antigen escape. We are particularly interested in exploring potential 
OR-AND-OR circuits that utilize dual synNotch receptors controlling dual CARs to 
achieve greatest coverage of heterogeneous antigen patterns frequently found within 
solid tumors. 
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Using different gates to selectively carve antigen recognition space 
The combinatorial antigen recognition circuits developed here should enable 
potent targeting of cancer cells with incredible discrimination from healthy cells. Our 
proof-of-concept circuits show that it is possible to custom tailor combinatorial synNotch 
T cells to target essentially any combination of three antigens. These initial studies 
targeted toy antigens not chosen to model particular cancer types. However, 
unpublished bioinformatic work by our collaborators suggests that there are a limited 
number of antigen recognition patterns necessary to sufficiently capture the vast 
majority of tumors, and we have developed circuits capable of targeting each of those 
pattern classes. The versatility and modularity of the synNotch receptor system means 
that such circuits should be able to target any cancer antigens with available recognition 
domain sequences (e.g. scFv). While these complex circuits will likely need to be 
optimized for new antigen target combinations, the known ability to independently tune 
each receptors’ features (e.x. binding domains, signaling domains, linkers) is of great 
advantage. If we can generate a large set of individually-validated synNotch receptors, 
CARs, and TCRs, then it could be a relatively “plug-and-chug” process to rapidly build 
and test new combinatorial antigen-sensing circuits for any given patient’s or group of 
patients’ tumor-specific antigen expression pattern. The modular multi-receptor circuits 
presented here provide a clear roadmap to engineer new T cells targeting any 
bioinformatically-identified tumor-specific antigen signature.  
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Synthetic cells meet synthetic materials - using biomaterials for spatiotemporal 
control of combinatorial antigen-sensing T cells 
 We developed a system in which a biocompatible engineered material can be 
used to provide a local, orthogonal cue to trigger expression of an antigen-specific 
receptor by an engineered cell.  These materials, receptors, and methods can be used 
with engineered therapeutic cells, such as T cells designed to specifically recognize and 
kill tumor cells.  This system provides novel capabilities to incorporate into the growing 
toolkit for engineering therapeutic cells with combinatorial antigen sensing circuits to 
enhance the precision of disease cell recognition.  We developed methods to engineer 
T cells to recognize an orthogonal cue on biocompatible particles and incorporated this 
detection into combinatorial antigen circuits that trigger antigen positive tumor cell killing 
only in the presence of our engineered particles. In this work, we synthesized 
biocompatible polymer (e.x. PLA or PLGA) microparticles presenting antigen/s and 
found that they are capable of activating synNotch receptors to induce CAR expression 
in primary human T cells.  In both in vitro experiments and in vivo mouse tumor studies, 
these synNotch T cells only kill cancer cells expressing the CAR antigen when 
synNotch antigen-presenting particles are added. To our knowledge, this is the first 
demonstration that T cells with combinatorial antigen recognition circuits can be 
regulated in vivo by material-presented antigen injected specifically at the tumor site.  
 The ability to incorporate material-presented antigen into combinatorial antigen-
sensing circuits has the potential to address several unmet needs. First, it is likely that 
there will be some cases in which secondary antigen/s cannot be identified to improve 
the tumor specificity of targeting a cancer-associated antigen.  By engineering T cells to 
	 178	
recognize a combination of particle-presented antigen and cancer cell antigen, it could 
now be possible to apply combinatorial antigen recognition to tumors lacking identifiable 
cancer-specific antigen expression patterns. Second, the ability to dynamically control 
the activity of therapeutic T cells once they are in the body is critical to help reduce the 
risk of adverse events.  By engineering T cells whose killing activity requires the 
presence of material-presented antigen, we created an ON-switch whereby dosing of 
the antigen particles can control T cell activity.  These particles can be synthesized 
using polymers that have different degradation kinetics, which in combination with 
variable dosing schedule enables tight control of T cells with combinatorial antigen 
recognition circuits. Third, tumors that do express a cancer-specific pattern of antigens 
could benefit from local injection of particles with significantly higher densities of one or 
more of the target antigens.  Some antigens identified in cancer-specific expression 
pairs are found at low levels.  The activity of most cellular receptors is known to 
correlate with target ligand expression levels; therefore, the potency of response by 
combinatorial antigen sensing T cells targeting a natural cancer-specific antigen 
combination could be enhanced by locally dosing particles presenting higher levels of 
one or more of the target antigens.  While much work needs to be done to optimize 
factors such as dosing schedule, using biocompatible antigen-presenting particles to 
control therapeutic cell activity in the body has the potential to enhance safety by 
enabling dynamic local user-control of engineered cells over the course of treatment.  
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Future outlook – challenges facing combinatorial antigen-sensing T cells 
 Engineered T cells are at an exciting and critical point in their development.  
Combinatorial antigen-sensing is just one of many strategies that could be used to 
enhance the impact of engineered T cell therapies.  In fact, it is obvious that solving the 
tumor recognition problem (the goal of combinatorial antigen-sensing circuits) alone will 
not be enough to develop effective therapies for solid tumors.  To achieve impactful 
results against solid tumors, T cells will need to be engineered with a variety of 
individual modules that can integrate into larger circuits to overcome the variety of 
barriers to treatment presented by most cancers.  Will it be possible to equip T cells with 
all the tools necessary to defeat solid tumors?  Even if we can develop all the individual 
modules, can we assemble them into integrated circuits that function in primary human 
T cells?   
 One major challenge facing the development of next-generation therapeutic T 
cells is the ability to reliably introduce large genetic circuits into these primary cells.  
Currently, clinically-approved CAR T cell therapies utilize lentivirus or retrovirus for cell 
engineering; however, these viruses only have room for have relatively small synthetic 
constructs (~5kb).  Moving forward, robust, clinical-grade methods for transducing T 
cells with increasingly large genetic payloads will be necessary.  Additionally, it would 
be desirable to control the location in which the payload is inserted into the genome, 
which is also not possible using lentivirus or retrovirus.  Improved gene-delivery 
technologies are required to take full advantage of new T cell engineering modules that 
are rapidly being developed.  
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Even given gene delivery and cell engineering limitations, the largest challenge 
moving forward for developing toolkits prototype in this work will likely be finding and/or 
generating robust preclinical models to test whether combinatorial antigen-sensing T 
cells can eliminate tumors while sparing healthy organs with ON-target OFF-tumor 
antigen expression. It is desirable to test the performance of engineered human T cells 
(versus mouse T cells) because those will ultimately be the therapeutic product. 
Additionally, it is desirable to test human T cells targeting human tumors.  However, to 
do so preclinically, this requires the use of immunocompromised mouse models.  
Mouse models are not usually ideal for testing combinatorial antigen-sensing T cells, 
because native healthy mouse organs express mouse antigens that cannot be 
recognized by human CAR T cells targeting human antigens expressed by human 
cancer cells.  Therefore, moving forward, combinatorial antigen-sensing T cells will 
need to be tested in in vivo models in which the CAR or TCR can cross-react with the 
mouse version of the antigen.  Possible solutions include the use of transgenic mice 
modified to express human antigens or antigen-specific receptors with binding domains 
capable of recognizing both mouse and human forms.  Now that we have improved our 
ability to engineer T cells with combinatorial antigen-sensing circuits, more rigorous 
preclinical studies should be undertaken to test these circuits before any significant 
effort is put into the development of novel targeting capabilities.   
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